Antifibrinolytic drugs for treating primary postpartum haemorrhage. by Shakur, Haleema et al.
LSHTM Research Online
Shakur, H; Beaumont, D; Pavord, S; Gayet-Ageron, A; Ker, K; Mousa, HA; (2018) Antifibrinolytic
drugs for treating primary postpartum haemorrhage. The Cochrane database of systematic reviews,
2. CD012964. ISSN 1469-493X DOI: https://doi.org/10.1002/14651858.CD012964
Downloaded from: http://researchonline.lshtm.ac.uk/4646707/
DOI: https://doi.org/10.1002/14651858.CD012964
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
https://researchonline.lshtm.ac.uk
Cochrane Database of Systematic Reviews
Antifibrinolytic drugs for treating primary postpartum
haemorrhage (Review)
Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA
Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA.
Antifibrinolytic drugs for treating primary postpartum haemorrhage.
Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012964.
DOI: 10.1002/14651858.CD012964.
www.cochranelibrary.com
Antifibrinolytic drugs for treating primary postpartumhaemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
14RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
21DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
23AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
38DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 1 Maternal mortality due to bleeding. . . . . . . . . . . . . . . . . . . . 41
Analysis 1.2. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 2 Maternal mortality due to bleeding (subgroup by mode of birth). . . . . . . . . . 42
Analysis 1.3. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 3 Maternal mortality due to bleeding (subgroup time from birth). . . . . . . . . . 43
Analysis 1.4. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 4 Maternal mortality (all causes). . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.5. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 5 Maternal mortality (all cause)(subgroup by mode of birth). . . . . . . . . . . . 45
Analysis 1.6. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 6 Maternal mortality (all cause) (subgroup time from birth). . . . . . . . . . . . 46
Analysis 1.7. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 7 Serious maternal morbidity (any). . . . . . . . . . . . . . . . . . . . 47
Analysis 1.8. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 8 Serious maternal morbidity (any) (subgroup by mode of birth). . . . . . . . . . 48
Analysis 1.9. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 9 Serious maternal morbidity (any) (subgroup by time of drug use from birth). . . . . . 49
Analysis 1.10. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 10 Serious maternal morbidity: multiple organ failure. . . . . . . . . . . . . . 50
Analysis 1.11. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 11 Serious maternal morbidity: maternal respiratory failure. . . . . . . . . . . . 50
Analysis 1.12. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 12 Serious maternal morbidity: Cardiac arrest. . . . . . . . . . . . . . . . . 51
Analysis 1.13. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 13 Serious maternal morbidity: Maternal renal failure. . . . . . . . . . . . . . 52
Analysis 1.14. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 14 Serious maternal morbidity: Hepatic failure. . . . . . . . . . . . . . . . 52
Analysis 1.15. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 15 Serious maternal morbidity: Maternal Seizure. . . . . . . . . . . . . . . . 53
Analysis 1.16. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 16 Maternal Intensive care admission. . . . . . . . . . . . . . . . . . . . 54
iAntifibrinolytic drugs for treating primary postpartum haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.17. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 17 Mortality from causes other than bleeding. . . . . . . . . . . . . . . . . 54
Analysis 1.18. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 18 Non-prespecified composite outcome: death or hysterectomy. . . . . . . . . . 55
Analysis 1.19. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 19 Blood loss 500 mL or more after randomisation. . . . . . . . . . . . . . . 55
Analysis 1.20. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 20 Blood loss 1000 mL or more after randomisation. . . . . . . . . . . . . . . 56
Analysis 1.21. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 21 Mean blood loss (mL). . . . . . . . . . . . . . . . . . . . . . . . 56
Analysis 1.22. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 22 Blood transfusion (all). . . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.23. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 23 Blood products transfusion. . . . . . . . . . . . . . . . . . . . . . 58
Analysis 1.24. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 24 Post randomisation additional uterotonics. . . . . . . . . . . . . . . . . 59
Analysis 1.25. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 25 Post randomisation additional uterotonics. . . . . . . . . . . . . . . . . 60
Analysis 1.26. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 26 Hysterectomy (provided it is not part of the intervention under investigation). . . . . 61
Analysis 1.27. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 27 Hysterectomy to control bleeding. . . . . . . . . . . . . . . . . . . . 61
Analysis 1.28. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 28 Post randomisation surgical intervention to control bleeding. . . . . . . . . . . 62
Analysis 1.29. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 29 Side effects of the intervention: any maternal vascular occlusive event. . . . . . . . 64
Analysis 1.30. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 30 Side effects of the intervention: maternal vascular occlusive events. . . . . . . . . 65
Analysis 1.31. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 31 Quality of Life: EQ5D Mobility. . . . . . . . . . . . . . . . . . . . 66
Analysis 1.32. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 32 Quality of Life: EQ5D Self care. . . . . . . . . . . . . . . . . . . . 66
Analysis 1.33. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 33 Quality of Life: EQ5D Usual activities. . . . . . . . . . . . . . . . . . 67
Analysis 1.34. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 34 Quality of Life: EQ5D Pain/discomfort. . . . . . . . . . . . . . . . . . 67
Analysis 1.35. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 35 Quality of Life: EQ5D Anxiety/depression. . . . . . . . . . . . . . . . . 68
Analysis 1.36. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment
of PPH, Outcome 36 Side effects of the intervention: neonatal vascular occlusive event. . . . . . . . . 68
Analysis 2.1. Comparison 2 Tranexamic acid versus rectal misoprostol for the treatment of PPH, Outcome 1 Mean blood
loss (mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
69APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
70CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
70DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
70SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
71DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiAntifibrinolytic drugs for treating primary postpartum haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antifibrinolytic drugs for treating primary postpartum
haemorrhage
Haleema Shakur1, Danielle Beaumont1 , Sue Pavord2, Angele Gayet-Ageron1,3, Katharine Ker1, Hatem A Mousa4
1Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK. 2Clinical Haematology, Oxford University
Hospitals, John Radcliffe Hospital, Oxford, UK. 3Division of Clinical Epidemiology, Medical Directorate, University Hospitals of
Geneva, Geneva, Switzerland. 4University Department of Obstetrics and Gynaecology, Fetal and Maternal Medicine Unit, Leicester
Royal Infirmary, Leicester, UK
Contact address: Haleema Shakur, Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London,
WC1E 7HT, UK. haleema.shakur@Lshtm.ac.uk.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New, published in Issue 2, 2018.
Citation: ShakurH,BeaumontD, Pavord S,Gayet-AgeronA,KerK,MousaHA.Antifibrinolytic drugs for treating primary postpartum
haemorrhage. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD012964. DOI: 10.1002/14651858.CD012964.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Postpartum haemorrhage (PPH) - heaving bleeding within the first 24 hours after giving birth - is one of the main causes of death of
women after childbirth. Antifibrinolytics, primarily tranexamic acid (TXA), have been shown to reduce bleeding in surgery and safely
reduces mortality in trauma patients with bleeding without increasing the risk of adverse events.
An earlier Cochrane review on treatments for primary PPH covered all the various available treatments - that review has now been split
by types of treatment. This new review concentrates only on the use of antifibrinolytic drugs for treating primary PPH.
Objectives
To determine the effectiveness and safety of antifibrinolytic drugs for treating primary PPH.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry
Platform (ICTRP) (28 May 2017) and reference lists of retrieved studies.
Selection criteria
Randomised controlled trials (RCTs), including cluster-randomised trials of antifibrinolytic drugs (aprotinin, TXA, epsilon-
aminocaproic acid (EACA) and aminomethylbenzoic acid, administered by whatever route) for primary PPH in women.
Participants in the trials were women after birth following a pregnancy of at least 24 weeks’ gestation with a diagnosis of PPH, regardless
of mode of birth (vaginal or caesarean section) or other aspects of third stage management.
We have not included quasi-randomised trials, or cross-over studies. Studies reported as abstracts have not been included if there was
insufficient information to allow assessment of risk of bias.
In this review we only identified studies looking at TXA.
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Data collection and analysis
Two review authors independently extracted data from each study using an agreed form.We entered data into ReviewManager software
and checked for accuracy.
For key review outcomes, we rated the quality of the evidence as ’high’, ’moderate’, ’low’ or ’very low’ according to the GRADE approach.
Main results
Three trials (20,412 women) met our inclusion criteria. Two trials (20,212 women) compared intravenous (IV) TXA with placebo or
standard care and were conducted in acute hospital settings (labour ward, emergency department) (in high-, middle- and low-income
countries).
One other trial (involving 200 women) was conducted in Iran and compared IV TXA with rectal misoprostol, but did not report on
any of this review’s primary or GRADE outcomes. There were no trials that assessed EACA, aprotinin or aminomethylbenzoic acid.
Standard care plus IV TXA for the treatment of primary PPH compared with placebo or standard care alone
Two trials (20,212 women) assessed the effect of TXA for the treatment of primary PPH compared with placebo or standard care alone.
The larger of these (The WOMAN trial) contributed over 99% of the data and was assessed as being at low risk of bias. The quality
of the evidence varied for different outcomes, Overall, evidence was mainly graded as moderate to high quality.
The data show that IV TXA reduces the risk of maternal death due to bleeding (risk ratio (RR) 0.81, 95% confidence interval (CI)
0.65 to 1.00; two trials, 20,172 women; quality of evidence: moderate). The quality of evidence was rated as moderate due to imprecision
of effect estimate. The effect was more evident in women given treatment between one and three hours after giving birth with no
apparent reduction when given after three hours (< one hour = RR 0.80, 95% CI 0.55 to 1.16; one to three hours = RR 0.60, 95% CI
0.41 to 0.88; > three hours = RR 1.07, 95% 0.76 to 1.51; test for subgroup differences: Chi² = 4.90, df = 2 (P = 0.09), I² = 59.2%).
There was no heterogeneity in the effect by mode of birth (test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%). There
were fewer deaths from all causes in women receiving TXA, although the 95% CI for the effect estimate crosses the line of no effect
(RR 0.88, 95% CI 0.74 to 1.05; two trials, 20,172 women, quality of evidence: moderate). Results from one trial with 151 women
suggest that blood loss of ≥ 500 mL after randomisation may be reduced (RR 0.50, 95% CI 0.27 to 0.93; one trial, 151 women;
quality of evidence: low). TXA did not reduce the risk of serious maternal morbidity (RR 0.99, 95% CI 0.83 to 1.19; one trial, 20,015
women; quality of evidence: high), hysterectomy to control bleeding (RR 0.95, 95% CI 0.81 to 1.12; one trial, 20,017 women; quality
of evidence: high) receipt of blood transfusion (any) (RR 1.00, 95% CI 0.97 to 1.03; two trials, 20,167 women; quality of evidence:
moderate) or maternal vascular occlusive events (any), although results were imprecise for this latter outcome (RR 0.88, 95% CI 0.54
to 1.43; one trial, 20,018 women; quality of evidence: moderate). There was an increase in the use of brace sutures in the TXA group
(RR 1.19, 95% CI 1.01, 1.41) and a reduction in the need for laparotomy for bleeding (RR 0.64, 95% CI 0.49, 0.85).
Authors’ conclusions
TXA when administered intravenously reduces mortality due to bleeding in women with primary PPH, irrespective of mode of birth,
and without increasing the risk of thromboembolic events. Taken together with the reliable evidence of the effect of TXA in trauma
patients, the evidence suggests that TXA is effective if given as early as possible.
Facilities for IV administration may not be available in non-hospital settings therefore, alternative routes to IV administration need to
be investigated.
P L A I N L A N G U A G E S U M M A R Y
Antifibrinolytic drugs to treat heavy bleeding after childbirth
What is the issue?
Antifibrinolytic drugs such as tranexamic acid (TXA) reduce breakdown of clots which form to stop bleeding and have been shown
to reduce bleeding in surgery and to safely reduce mortality in patients with bleeding following injury without increasing the risk of
adverse events. This review assesses the safety and effects of antifibrinolytic drugs in women with primary postpartum haemorrhage
(PPH) (heavy bleeding within the first 24 hours after giving birth).
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An earlier Cochrane review on treatments for primary PPH covered all the various available treatments; that review has now been split
by types of treatment. This new review concentrates only on the use of antifibrinolytic drugs for treating primary PPH.
Why is this important?
Postpartum haemorrhage is one of the main causes of death of women after childbirth and can also cause anaemia and other serious
complications.
What evidence did we find?
We searched for evidence on 28 May 2017 and found three trials which met the inclusion criteria for the review. Participants in the
trials were women after birth following a pregnancy of at least 24 weeks’ gestation with a diagnosis of PPH, regardless of whether they
had a vaginal or caesarean section. We identified three trials (involving 20,412 women). However, one of the trials (based in Iran)
did not report important outcomes, therefore, our findings are based on two trials (involving 20,212 women) conducted in hospital
settings in high-, middle- and low-income countries. One was a large trial that included more than 20,000 women, and both studies
looked at the effectiveness and safety of intravenous (IV) TXA compared with placebo (dummy treatment) or no treatment. In both
trials TXA was given in addition to usual care to treat bleeding. The trial contributing most of the information to the review was at
low risk of bias.
Our results show that TXA reduces the risk of maternal death due to bleeding (quality of evidence: moderate). There were fewer deaths
from all causes but the findings were uncertain (quality of evidence: moderate). In one trial with a small sample size additional blood loss
of 500 mL or more was also reduced (151 women; quality of evidence: low). TXA had little or no effect on the risk of serious maternal
illness (quality of evidence: high), or complications such as stroke or deep venous thrombosis (quality of evidence: moderate). Rates of
hysterectomy to control bleeding (quality of evidence: high) and blood transfusion (quality of evidence: moderate) were similar for women
receiving TXA versus placebo. There was an increase in one surgical intervention (brace sutures) in the TXA group and a reduction in
another (laparotomy to control bleeding) but there were no clear differences between groups for other surgical and invasive procedures.
What does this mean?
TXA when administered intravenously was effective in reducing mortality due to bleeding when given within three hours in women
with primary postpartum haemorrhage without increasing the risk of other complications.
Facilities for IV administration is not available in some settings so future research could look at whether TXA is effective and safe if
given by other methods.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Standard care plus IV tranexamic acid compared to placebo or standard care alone for treating primary postpartum haemorrhage
Patient or population: women with primary postpartum haemorrhage following vaginal or caesarean birth
Setting: acute hospital (labour ward, emergency department) (in high-, m iddle- and low-income countries)
Intervention: standard care plus tranexamic acid
Comparison: placebo or standard care alone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo or
standard care alone
Risk with standard care
plus tranexamic acid
Maternal mortality due
to bleeding
Study populat ion RR 0.81
(0.65 to 1.00)
20,172
(2 RCTs)
⊕⊕⊕©
MODERATE 1
The est imable data are
f rom a single study with
a large sample size19 per 1000 15 per 1000
(12 to 19)
Maternal mortality (all
causes)
Study populat ion RR 0.88
(0.74 to 1.05)
20,172
(2 RCTs)
⊕⊕⊕©
MODERATE 2
The est imable data are
f rom a single study with
a large sample size25 per 1000 22 per 1000
(19 to 27)
Serious maternal mor-
bidity (any)
Study populat ion RR 0.99
(0.83 to 1.19)
20,015
(1 RCT)
⊕⊕⊕⊕
HIGH
22 per 1000 22 per 1000
(19 to 27)
Blood loss 500 mL or
more af ter randomisa-
t ion
Study populat ion RR 0.50
(0.27 to 0.93)
151
(1 RCT)
⊕⊕©©
LOW 34
311 per 1000 155 per 1000
(84 to 289)
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Blood transfusion (any) Study populat ion RR 1.00
(0.97 to 1.03)
20,167
(2 RCTs)
⊕⊕⊕©
MODERATE 5
Most of the data are
f rom a single study with
a large sample size542 per 1000 542 per 1000
(525 to 558)
Surgical intervent ion to
control bleeding: Hys-
terectomy
Study populat ion RR 0.95
(0.81 to 1.12)
20,017
(1 RCT)
⊕⊕⊕⊕
HIGH
30 per 1000 28 per 1000
(24 to 33)
Side ef fects of the in-
tervent ion: Any mater-
nal vascular occlusive
event
Study populat ion RR 0.88
(0.54 to 1.43)
20,018
(1 RCT)
⊕⊕⊕©
MODERATE 2
3 per 1000 3 per 1000
(2 to 5)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Wide 95%CI that includes the line of no ef fect (0.65 to 1.00) (-1)
2 Wide 95%CI crossing the line of no ef fect (-1)
3 Single study with design lim itat ions (no blinding) (-1)
4 Estimate based on small sample size (-1)
5 Moderate stat ist ical heterogeneity and may be clinical heterogeneity (-1)
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B A C K G R O U N D
Description of the condition
Each year, worldwide, over 300,000 women die in childbirth (
Alkema 2016). Primary postpartum haemorrhage (PPH) is one of
the most common causes with a global prevalence rate of about
6% (Carroli 2008) and accounts for 27% of maternal deaths (Say
2014).
Traditionally, primary PPH is defined as bleeding from the gen-
ital tract of 500 mL or more in the first 24 hours following de-
livery of the baby (Abou Zahr 1991; Cunningham 1993; WHO
2012). Women delivering by caesarean section lose more blood
on average than women who have vaginal birth; therefore, 1000
mL is commonly used as a cut-off for significant blood loss after
caesarean section. Blood loss up to 500 mL at delivery is regarded
as ’physiological’, and a healthy pregnant woman can cope with
it without difficulty (Gyte 1992; Ripley 1999). However, most
deaths frombleeding occur in low-resource settings where anaemia
is prevalent and even a small amount of blood loss can affect a
woman adversely (Ronsmans 2006). Primary PPH can be caused
by inefficient uterine contraction (uterine atony), trauma, retained
placenta, retained parts of the placenta, vaginal or cervical tears,
uterine rupture, clotting disorders and uterine inversion.
Major primary PPH can lead to significant morbidity including
shock, renal failure, respiratory failure and/or liver failure (Bonnar
2000). Lack of easy access to treatment and inadequate intensive
care and blood bank facilities are additional contributing factors
that lead to high morbidity and mortality rates in low-income
countries (Khan 2006; Say 2014; WHO 2015).
Treatment of primary PPH requires a multidisciplinary approach
(WHO 2012). Uterotonics are usually given as the first line of
treatment. Both surgical and non-surgical techniques including
compression devices and radiological measures are also used to
control bleeding (WHO 2012). Most deaths occur soon after de-
livery (Khan 2006; Knight 2007), therefore rapid control of haem-
orrhage is essential to reduce death and serious complications.
Description of the intervention
Antifibrinolytic drugs, tranexamic acid (TXA), epsilon-
aminocaproic acid (EACA), aprotinin and aminomethylbenzoic
acid, are used as inhibitors of clot breakdown (fibrinolysis) and
may be administered by a variety of routes; intravenous, intramus-
cular, oral, sublingual, buccal and topical (direct application to the
bleeding surfaces).
TXA has been shown to reduce the risk of bleeding in surgery
(Ker 2012). It has been shown to reduce death due to bleeding
in trauma, with treatment as early as possible being more effec-
tive. Treatment after three hours of injury had no effect and could
even be harmful (Roberts 2013). TXA is used to reduce blood loss
in women with heavy menstrual bleeding (Naoulou 2012). Cur-
rently, the use of TXA is recommended for the treatment of pri-
mary PPH if oxytocin and other uterotonics fail to stop bleeding,
or if it is thought that the bleeding may be partly due to trauma
(WHO 2012).
The risk of postpartum venous thromboembolism is highest in
the immediate postpartum period (Tepper 2014). Because TXA
inhibits fibrinolysis, it carries a potential risk of increasing throm-
boembolic events.
TXA passes into breast milk in very low concentrations, approxi-
mately one hundredth of the concentration in the maternal blood
(Nilsson 1980) and risk of vascular occlusive events in breastfed
infants is unknown.
How the intervention might work
Antifibrinolytic drugs work through influencing blood coagula-
tion. TXA and EACA are synthetic derivatives of the amino acid
lysine, which work by blocking lysine binding sites on plasmino-
gen molecules and can prevent clot breakdown, thereby reducing
bleeding (Novikova 2015). TXA is seven to 10 times more potent
than EACA (Nilsson 1980). Aminomethylbenzoic acid inhibits
fibrinolysis and has antithrombin activity, both of which result
in delays of clot resorption (Westlund 1982). Aprotinin is a ser-
ine protease inhibitor which acts by inhibiting plasmin and sub-
sequent fibrin clot breakdown (Westaby 1993) There is contro-
versy over the use of aprotinin, whose license has been restricted
or withdrawn in some countries.
During the first hours following birth, an increase in fibrinolytic
activity has been reported (Gerbasi 1990). Also, an increased fib-
rinolytic activity is observed in women with PPH. Serum concen-
tration of tissue plasminogen activator (tPA) doubles within one
hour of the birth and thereafter, the tPA concentration falls steeply
(Kruithof 1987). On the other hand, levels of the plasminogen ac-
tivator inhibitors (PAI-1 and PAI-2) are increased around the time
of birth and remain so for several days. We might therefore expect
antifibrinolytics would be most effective when given soon after
birth, when tPA levels are highest. Active PPH has been shown
to be associated with an early increase in D-dimers and plasmin-
anti-plasmin complexes and that D-dimers can be inhibited by
the administration of TXA (Ducloy-Bouthors 2016). In PPH, fib-
rinogen levels decline (Huissoud 2009). This fall may be a reflec-
tion of several ongoing processes, including: factor consumption,
dilution (from fluid used for resuscitation), fibrinolysis and fib-
rinogenolysis. We therefore hypothesise that early administration
of an antifibrinolytic drug could reduce blood loss by interrupting
the vicious circle of fibrinolysis and fibrinogen depletion.
Why it is important to do this review
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The last review of treatments for primary PPH in the Cochrane
Library was in 2014 (Mousa 2014) and it covered all the various
treatment modalities. PPH remains a leading cause of maternal
mortality and morbidity especially in poor-resource countries and
there is a need to update the knowledge about safe and effective
treatments for PPH. Specifically, that a review dedicated to assess-
ing the effectiveness of antifibrinolytic drugs for the treatment of
primary PPH is conducted to inform local and national practices
and guide clinicians and midwives to understand the role of these
drugs when caring for women with primary PPH.
TXA is currently included in the recommendations of the World
Health Organization (WHO) for the treatment of primary PPH
(WHO2012) based on the results of its efficacy in trauma patients
(CRASH-2 2010; Roberts 2013) and perioperative blood loss(Ker
2013). A review is needed to inform the update of the WHO
guidelines on the use of antifibrinolytics for PPH.
O B J E C T I V E S
To determine the effectiveness and safety of antifibrinolytic drugs
for treating primary postpartum haemorrhage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) including cluster-ran-
domised trials. We have not included quasi-randomised trials, or
cross-over studies. Studies reported as abstracts have not been in-
cluded if there was insufficient information to allow assessment of
risk of bias.
Types of participants
Inclusion criteria
Women after birth following a pregnancy of at least 24 weeks’
gestation with a diagnosis of primary postpartum haemorrhage
(PPH), regardless of mode of birth (vaginal or caesarean section)
or other aspects of third stage management.
As it may be difficult to obtain an accurate measurement of blood
loss, PPH may be defined in different ways in trials:
• women with blood loss of 500 mL or more and/or
• women with primary PPH requiring blood transfusion and/
or blood products and/or
• women with a clinical diagnosis of primary PPH (as defined
by trialists).
Exclusion criteria
• Women with PPH with gestational age less than 24 weeks.
Types of interventions
The interventions considered are the antifibrinolytic drugs: apro-
tinin, tranexamic acid (TXA), epsilon-aminocaproic acid (EACA)
and aminomethylbenzoic acid administered by whatever route
(e.g. intravenous, oral).
Comparisons
• Aprotinin plus standard care versus placebo, or standard
care alone
• TXA plus standard care versus placebo, or standard care
alone
• EACA plus standard care versus placebo, or standard care
alone
• Aminomethylbenzoic acid plus standard care versus
placebo, or standard care alone
• Standard care plus systemic aprotinin, TXA, EACA and
aminomethylbenzoic acid versus standard care plus topical
antifibrinolytic
• Standard care plus one antifibrinolytic drug therapy versus
another
Because PPH is a dynamic process, it is expected that women with
primary PPH will have received other interventions to control
the bleeding. Due to the random allocation of antifibrinolytic
drugs, we anticipated thatwewould observe a similar proportionof
women receiving other interventions in both comparison groups.
Types of outcome measures
Primary outcomes
• Mortality due to bleeding
• All-cause mortality*
• Serious maternal morbidity (renal or respiratory failure,
cardiac arrest or multiple organ failure)
Secondary outcomes
• Mortality from causes other than bleeding
• Shock as defined by trialist*
• Coagulopathy as defined by trialist*
• Number of women with total blood loss 500 mL or more
after randomisation*
• Number of women with total blood loss 1000 mL or more
after randomisation*
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• Mean blood loss (mL) (trialist defined)*
• Blood transfusion (red cell or whole blood)*
• Blood product transfusion*
• Post-randomisation additional uterotonic used to control
bleeding
• Post-randomisation surgical interventions used to control
bleeding (arterial ligation, compressive, uterine sutures, arterial
embolisation, laparotomy)
• Post-randomisation non-surgical intervention to control
bleeding (uterine packing, bimanual uterine massage,
tamponade, external aortic compression and compression
garments)
• Admission to higher level of care*
• Hysterectomy (provided it is not part of the intervention
under investigation)*
• Post-randomisation additional haemostatic agents used*
• Side effects of intervention (both maternal and neonate);
specifically vascular occlusive events (myocardial infarction,
stroke, deep vein thrombosis or pulmonary embolism) and renal
failure
Other outcomes
• Days in hospital
• Breastfeeding (defined as any breastfeeding at hospital
discharge)*
• Maternal satisfaction with therapy (trialist defined)*
• Quality of life, including physiological activity and social
and emotional changes (sense of well-being) (trialist defined)*
(*outcomes form part of an outcome set that will be used in all
PPH reviews)
NOTE:
• We anticipated that assessment of blood loss could vary
between trials. We considered that measurement of blood and
blood clots in jars and weighing of linen are likely to be more
precise than clinical judgement. The latter is known to
underestimate blood loss.
• The way of reporting the amount of loss as ’greater than’ or
’greater than or equal to’ a certain cut-off level (e.g. greater than
500 mL or greater than or equal to 500 mL) may affect the total
reported amount of blood loss.
• Antifibrinolytics such as TXA may be present in breast milk
in small quantities. If neonates are breastfed, they are also
exposed to the intervention. Side effects of the intervention were
assessed in the neonates who were breastfed.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (28 May 2017).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activi-
ties described above is reviewed. Based on the intervention de-
scribed, each trial report is assigned a number that corresponds
to a specific Pregnancy and Childbirth review topic (or topics),
and is then added to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searchedClinicalTrials.gov and theWHOInterna-
tional Clinical Trials Registry Platform (ICTRP) for unpublished,
planned and ongoing trial reports (28 May 2017) using the search
methods detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
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Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted a third review author.
We have included a study flow diagram mapping out the number
of records identified, included and excluded (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. Assessments re-
garding inclusion and exclusion,GRADE and risk of bias were car-
ried out by review authors not involved in the conduct of included
trials. However, review authors involved in one of the included
studies were involved in the selection of outcomes and the inter-
pretation of the data. We resolved discrepancies through discus-
sion or, if required, we consulted a third review author.We entered
data into Review Manager software (RevMan 2014) and checked
for accuracy. When information regarding any of the above was
unclear, we attempted to contact authors of the original reports to
provide further details.
As part of data extraction we collected information on study de-
sign and setting, trial dates, participant characteristics (including
information on cause of bleeding and its severity where available),
details of routine care provided and the intervention given (drug,
route and dose), the outcomes assessed, the source of study fund-
ing and any conflicts of interest stated by the investigators.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results.We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We have stated whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information was reported, or sup-
plied by the trial authors, we have re-included missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
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• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
Wedescribed for each included study howwe investigated the pos-
sibility of selective outcome reporting bias and what we found.We
noted whether or not there was prospective registration, prospec-
tive protocol publication, plagiarism, and whether outcome re-
ported matched outcomes pre-specified in trial protocols or regis-
trations.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above))
We described for each included study any important concerns we
have about other possible sources of bias (e.g. baseline imbalance
between randomised groups).
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in the Handbook (Higgins
2011). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we considered
it likely to impact on the findings. Data permitting, we planned
to explore the impact of the level of bias through undertaking
sensitivity analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
The quality of the evidence was assessed using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence.
Where data were available, we planned to use GRADE to assess
the overall quality of the evidence for our main comparisons.
• TXA versus placebo or standard care
• Aprotinin versus placebo or standard of care
• EACA versus placebo or standard of care
• Aminomethylbenzoic acid versus placebo or standard of
care
• Standard care plus systemic aprotinin, TXA, EACA and
aminomethylbenzoic acid versus standard care plus topical
antifibrinolytic
• Standard care plus one antifibrinolytic drug therapy versus
another
We assessed the following outcomes.
• Maternal mortality due to bleeding
• Maternal mortality (all causes)
• Serious maternal morbidity (renal or respiratory failure,
cardiac arrest or multiple organ failure)
• Surgical intervention to control bleeding (hysterectomy for
bleeding)
• Side effects of intervention: specifically maternal vascular
occlusive events (any)
• Blood loss equal to or greater than 500 mL after
randomisation
• Blood transfusion (any)
(Grade outcomes are included in our review ’Summary of findings’
table.)
GRADEproGuidelineDevelopmentTool was used to import data
from Review Manager 5.3 (RevMan 2014) in order to create a
’Summary of findings’ table. A summary of the intervention ef-
fect and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the qual-
ity of the body of evidence for each outcome. The evidence can
be downgraded from ’high quality’ by one level for serious (or
by two levels for very serious) limitations, depending on assess-
ments for risk of bias, indirectness of evidence, serious inconsis-
tency, imprecision of effect estimates or potential publication bias.
Evidence was graded by two independent assessors and checked
by a third assessor (Therese Dowswell, Lambert Felix (CPC) and
Angele Gayet-Ageron)
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials. We planned to use
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the standardised mean difference to combine trials that measured
the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually-randomised trials. No such trials were
identified for this version of the review. If such trials are included
in future updates we will adjust their sample sizes using the meth-
ods described in the Handbook using an estimate of the intraclus-
ter correlation coefficient (ICC) derived from the trial (if possi-
ble), from a similar trial or from a study of a similar population.
If we use ICCs from other sources, we will report this and con-
duct sensitivity analyses to investigate the effect of variation in the
ICC. If we identify both cluster-randomised trials and individu-
ally-randomised trials, we plan to synthesise the relevant informa-
tion. We will consider it reasonable to combine the results from
both if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
We have not included cross-over trials.
Other unit of analysis issues
If in future updates we identify trials withmore than two treatment
groups, we will use methods described in theHandbook section
16.4.7. in order to avoid double-counting.
Dealing with missing data
For included studies, we noted levels of attrition. Data permitting,
we planned to explore the impact of including studies with high
levels of missing data in the overall assessment of treatment effect
by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all par-
ticipants randomised to each group in the analyses, and all par-
ticipants analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial is the number
randomised minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We planned to assess statistical heterogeneity in each meta-analy-
sis using the Tau², I² and Chi² statistics. The indicator I2 which
reflects the part of variance between studies that is due to factors
other than chance, as well as Cochran’s Q. We regarded hetero-
geneity as substantial if I² was greater than 30% and either a Tau²
was greater than zero or a low P value (less than 0.10) was obtained
in the Chi² test for heterogeneity”).
If important heterogeneity was identified (I2 > 30%), we planned
to explore it using pre-defined heterogeneity factors: type of de-
livery, severity of PPH, time from delivery and route of adminis-
tration.
Assessment of reporting biases
If, in future updates, there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it is reasonable to assume that studies estimate
the same underlying treatment effect: i.e. where trials examined
the same intervention, and the trials’ populations and methods
were judged sufficiently similar. If there was clinical heterogeneity
sufficient to expect that the underlying treatment effects differed
between trials, or if substantial statistical heterogeneity was de-
tected, we planned to use random-effects meta-analysis to produce
an overall summary ,if an average treatment effect across trials was
considered clinically meaningful.
Subgroup analysis and investigation of heterogeneity
Data permitting, we planned to investigate substantial heterogene-
ity using subgroup analyses.
To attempt to identify possible factors thatmaymediate the clinical
effect of treatment, where datawere available we planned subgroup
analysis by:
1. type of delivery (vaginal versus caesarean);
2. severity of haemorrhage at randomisation (blood loss ≤
1000 mL, > 1000 mL);
3. hours from giving birth to randomisation (< 1, 1 to 3, > 3
hours);
4. route of administration (intravenous, intramuscular,
sublingual, buccal, topical, oral).
We carried out subgroup analysis for our primary outcomes only
(maternal mortality due to bleeding, all-cause mortality, serious
maternal morbidity (renal or respiratory failure, cardiac arrest or
multiple organ failure)).
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We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi2 statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
We planned to carry out sensitivity analysis for studies at high risk
of bias for attrition (temporarily excluding studies with > 20% loss
to follow-up from the analyses). We did not carry out this planned
analysis as studies contributing data had low loss to follow-up.
R E S U L T S
Description of studies
Results of the search
The search retrieved 42 reports relating to 15 trials (see: Figure
1). Of the 15 trials, three met the inclusion criteria of the review,
nine were excluded, one is awaiting further assessment (pending
further information from the trialist - see Characteristics of studies
awaiting classification), and there are two ongoing trials. Details
of ongoing trials are set out in Characteristics of ongoing studies
tables.
Included studies
Design
Three trials (involving 20,412 women) met our inclusion criteria
(Ducloy-Bouthors 2011; Sahaf 2014; Woman Trial 2017). One
trial (Sahaf 2014) reported results for only one of the review’s
outcomes: estimated blood loss and does not otherwise contribute
to the data and analysis. For all other outcomes two trials have
contributed data on 20,212 women to our data and analyses tables
(Ducloy-Bouthors 2011; Woman Trial 2017).
Sample sizes
The Woman Trial 2017, a multi-centre trial recruited 20,060
women with little loss to follow-up, contributed the most data to
the review. A trial carried out in France (Ducloy-Bouthors 2011)
recruited 152 women. The additional trial meeting our inclusion
criteria recruited 200 women (Sahaf 2014).
Setting
For most outcomes two trials contributed data to the review.
One was a multi-centre randomised controlled trial with 20,060
women (Woman Trial 2017); in this study women were recruited
from hospital settings in high- (UK: 569 women), and low- and
middle-income countries (Nigeria: 5711; Pakistan: 5282;Uganda:
2235; Kenya: 1031; Cameroon: 893; Sudan: 860; Tanzania: 538;
Nepal: 533; Zambia: 496; Albania: 485; Democratic Republic
of Congo: 457; Bangladesh: 325; Ethiopia: 302; Burkina Faso:
142; Jamaica: 73; Ghana: 41; Papua New Guinea: 38; Egypt:
33; Colombia: 8; Cote d’Ivoire: 8). Women were recruited to
the WOMAN trial between 2010 and 2016. The second trial
(Ducloy-Bouthors 2011) was conducted in France in eight cen-
tres (five tertiary care centres and three secondary care obstetric
centres: 152 women). This study recruited women between 2005
to 2008.
The remaining trial was carried out in Iran (Sahaf 2014).
Participants
In all trials women were recruited with postpartum haemorrhage
(PPH).
TheDucloy-Bouthors 2011trial recruitedwomenwith PPH>800
mL within hours after vaginal birth. Exclusion criteria included
women less than 18 years old, no informed consent, caesarean sec-
tion, known haemostatic abnormality, and history of thrombosis
or epilepsy.
The Woman Trial 2017 recruited women aged 16 years or older
with clinically diagnosed PPH (estimated blood loss after vaginal
birth > 500 mL, or > 1000 mL after caesarean section or estimated
blood loss enough to compromise the haemodynamic status of the
woman). Women were randomised only if the clinician responsi-
ble for their care was “substantially uncertain” as to whether or not
to use tranexamic acid (TXA) in a particular woman with PPH.
Exclusion criteria included any clear indication or contraindica-
tion to TXA (e.g. a known thromboembolic event during preg-
nancy).
In the Sahaf 2014 trial women were recruited after caesarean or
vaginal birth with PPH (500 mL to 1500 mL) after receiving
routine therapies for controlling bleeding.
Interventions and comparisons
All trials examined TXA to treat PPH.
In the Ducloy-Bouthors 2011 trial, women in the experimental
group were given a loading dose of 4 g TXA mixed with 50 mL
saline, administered intravenously (IV) over one hour followed by
a maintenance dose of 1 g/hour for six hours (n = 78), while those
in the comparison group received usual care (no TXA) (n = 74).
In theWoman Trial 2017, following routine care for PPH, women
were randomised. Those in the intervention group were given IV
TXA 1 g as an IV bolus over 10 minutes; if after 30 minutes
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bleeding continued, or had stopped and restarted within 24 hours
of the first dose, women were given a second dose (n = 10,051).
Women in the control group received placebo (sodium chloride
0.9% contained in ampoules and packaging with identical appear-
ance to active treatment) with the same regimen as that used in
the experimental group (n = 10,009).
In the Sahaf 2014 trial, 100 women randomised to the interven-
tion group received 1 g IV TXA repeated after 30 minutes; the
comparison group (100 women) received 1000 micrograms (mcg)
rectal misoprostol (five 200 mcg tablets). Prostatglandin F2 was
administered in case of treatment failure in both groups.
Outcomes
Only one of our included trials, Woman Trial 2017, was suffi-
ciently powered to identify differences between groups for our
primary outcomes (mortality and serious maternal morbidity), al-
though mortality was reported in theDucloy-Bouthors 2011 trial.
Cause of death (death due to bleeding and other causes) was re-
ported in theWoman Trial 2017 along with serious maternal com-
plications (renal failure, cardiac failure, respiratory failure, hep-
atic failure, and seizures). Hysterectomy was reported in two trials
(Ducloy-Bouthors 2011; Woman Trial 2017), and other surgical
and invasive interventions (including intrauterine tamponade; em-
bolisation; brace sutures (B-Lynch/Cho); artery ligation, to achieve
haemostasis; hysterectomy and laparotomy done after randomisa-
tion to control bleeding) in theWoman Trial 2017. The number of
women experiencing deep venous thrombosis or other vascular oc-
clusive events was reported byDucloy-Bouthors 2011 andWoman
Trial 2017 and less serious side effects in the Ducloy-Bouthors
2011 trial. Blood transfusion or blood product transfusion was re-
ported in two trials (Ducloy-Bouthors 2011; Woman Trial 2017),
and estimated blood loss in two trials (Ducloy-Bouthors 2011;
Sahaf 2014). Other outcomes reported in the Woman Trial 2017
included maternal quality of life (measured using the EQ5D at
hospital discharge or in hospital at 42 days after randomisation)
and neonatal outcomes (death in breastfed infants or neonatal
thromboembolic events).
Sources of support and conflicts of interest
The Ducloy-Bouthors 2011 trial was funded by the French Min-
istry of Health. TheWoman Trial 2017 was funded by the London
School of Hygiene & Tropical Medicine, Pfizer, UK Department
of Health, Wellcome Trust, and Bill & Melinda Gates Founda-
tion. The Sahaf 2014 trial was unfunded.
All three trials stated that there were no conflicts of interest.
GIven the sample size of theWomanTrial 2017 this trial dominates
our results section.
Excluded studies
Nine trials were excluded from the review; although these studies
examined treatments for PPH, these trials did not examine the
use of antifibrinolytic drugs (Ahonen 2013; Bruynseels 2016;
Ducloy-Bouthors 2016; Lavigne-Lissalde 2015; Paidas 2015; von
Beckerath 2016; Wikkelso 2015). One trial (Sadeghipour 2013),
examined the treatment of uterine atony. In one study (Wiznitzer
2011), the intervention was a dressing for vaginal tears, however
there was no clear evidence from the trial registration that women
had PPH. See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2; Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
In the two trials contributing data to the main comparison in the
review, the methods used to generate the randomisation sequence
were assessed as low risk of bias. In the Woman Trial 2017 an ex-
ternal randomisation service was used and in theDucloy-Bouthors
2011 trial a computer-generated sequence was used. In the re-
maining trial (Sahaf 2014), the method used to generate the ran-
domisation sequence was assessed as unclear. While the report for
the Sahaf 2014 trial mentioned a computer programme, it stated
also that the sample was “divided into two equal groups” and we
were unable to verify the methods used.
Allocation concealment at the point of randomisation was assessed
as low risk of bias in the Woman Trial 2017. In the remaining
studies there was insufficient information on methods or methods
were unclear.
Blinding
Performance bias: The Woman Trial 2017 was placebo-controlled.
In this trial, women and staff providing care were unlikely to be
aware of treatment allocation. In the Ducloy-Bouthors 2011 trial
there was no placebo, and women and staff would not be blind
to treatment. The Sahaf 2014 trial compared different treatments.
Both Ducloy-Bouthors 2011 and Sahaf 2014 were assessed as high
risk of bias for this domain.
Detection bias: In the Woman Trial 2017, it was stated that the
randomisation code was not broken until the end of the trial and
all staff and investigators were blind to treatment allocation until
that point. In the Ducloy-Bouthors 2011 trial it was stated that
staff were unaware of allocation although the women received
different treatments so it is not clearwhether or not lack of blinding
impacted on outcomes. In the remaining trial there was no attempt
at blinding and this study was assessed as high risk of bias (Sahaf
2014).
Incomplete outcome data
The two trials contributing data to the main comparison in the
review (Ducloy-Bouthors 2011;WomanTrial 2017) had low losses
to follow-up (low risk of bias). The remaining trial did not provide
information on loss to follow-up or whether or not there were any
missing data - we assessed this trial as having an unclear risk of
attrition bias (Sahaf 2014).
Selective reporting
For the Woman Trial 2017 selective reporting bias was assessed as
low risk of bias. The trial protocol was published before recruit-
ment to the trial, although less emphasis was put on the hysterec-
tomy component of the composite primary outcome, all relevant
outcomes were reported in the main trial report or data were pro-
vided by the trialists. In the remaining trials (Ducloy-Bouthors
2011; Sahaf 2014), registration did not occur before recruit-
ment or data for all relevant outcomes were not fully reported
(both assessed as unclear risk of reporting bias). The author of
Ducloy-Bouthors 2011trial kindly provided additional data.
Other potential sources of bias
The two trials contributing data to the main review comparison
were assessed as being at low risk of bias for other sources of bias
(Ducloy-Bouthors 2011; Woman Trial 2017). The other trial (
Sahaf 2014) provided little information on methods and there
were baseline differences between groups that may have impacted
on outcomes - we assessed this trial as be at unclear risk of other
bias.
Effects of interventions
See: Summary of findings for the main comparison Standard
care plus IV tranexamic acid compared to placebo or standard care
alone for treating primary postpartum haemorrhage
Standard care plus IV tranexamic acid (TXA) versus
placebo or standard care alone for the treatment of
postpartum haemorrhage (PPH) (Comparison 1)
Primary outcomes
Maternal mortality due to bleeding
Two trials were included in this analysis, but in the Ducloy-
Bouthors 2011 trial there were no events, therefore all estimable
data are from theWoman Trial 2017. TXA probably reduces mor-
tality due to bleeding in women with PPH (risk ratio (RR) 0.81,
95% confidence interval (CI) 0.65 to 1.00; 20,172 women, mod-
erate-quality evidence); the reduction in death observed equates to
four fewer deaths per 1000 women in the TXA group (19 deaths
per 1000 in the placebo group versus 15 deaths per 1000 in the
TXA group (95% CI 12 to 19)). Analysis 1.1.
Subgroup analysis
We carried out subgroup analysis by mode of birth and time from
birth.
The effect of TXA on death due to bleeding did not differ by
the type of birth, with the treatment effect being very similar in
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women who had given birth vaginally or by caesarean section (test
for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%).
Analysis 1.2.
Women receiving treatment with TXA between one and three
hours after the birth had a reduced risk of death from bleeding
compared with placebo. For women who received treatment in
the first hour and after three hours of birth, there was no clear
differences between the intervention and control groups (test for
subgroup differences: Chi² = 4.90, df = 2 (P = 0.09), I² = 59.2%).
Analysis 1.3.
Maternal mortality (all causes)
All estimable data for this analysis are from theWoman Trial 2017.
TXA reduced mortality from all causes although the 95% CI for
the effect estimate crosses the line of no effect (RR 0.88, 95% CI
0.74 to 1.05; 20,172 women, moderate-quality evidence). Analysis
1.4.
Subgroup analysis
Subgroup analysis suggested that mode of birth made little or no
difference to the treatment effect (test for subgroup differences:
Chi² = 0.14, df = 1 (P = 0.71), I² = 0%). Analysis 1.5. Time from
birth did appear to have an impact on the treatment effect with
women receiving TXA between one and three hours after the birth
having a reduced risk of death compared with placebo, although
the subgroup interaction test did not show a clear difference be-
tween the three subgroups (test for subgroup differences: Chi² =
3.25, df = 2 (P = 0.20), I² = 38.5%). Analysis 1.6.
Serious maternal morbidity (any)
All estimable data for this analysis are from theWoman Trial 2017.
There was little or no difference between TXA and placebo for
the number of women with any serious morbidity (renal failure,
respiratory failure, cardiac arrest or multiple organ failure) (RR
0.99, 95%CI 0.83 to 1.19; 20,015 women, high-quality evidence);
22 women per 1000 suffered a serious morbidity in both arms of
the trial. Analysis 1.7.
Subgroup analysis identifiedno clear differences in treatment effect
for women having vaginal or caesarean birth, or by timing of drug
administration. Analysis 1.8; Analysis 1.9.
Additional planned subgroup analysis: For primary outcomes,
we had planned subgroup analysis by severity of haemorrhage
(women with blood loss≤ 1000 mL versus blood loss > 1000 mL).
We were unable to carry out this planned analysis as no separate
data were available for women in these two groups. We were also
unable to explore the route of administration (e.g. IV versus oral)
as in both included trials the method of administration was IV.
We will carry out planned additional analysis in updates if data
become available.
Serious maternal morbidity (by type)
The number of women experiencing specific types of severe mor-
bidity was also reported.
Multiple organ failure was reported in both trials included in
the analysis; the Ducloy-Bouthors 2011 trial reported no events,
therefore all estimable data are from theWoman Trial 2017. There
was little or no difference between women receiving TXA versus
placebo for this outcome, with approximately 1% of women in
both arms of the trial suffering multiple organ failure (RR 0.94,
95% CI 0.71 to 1.23; 20,168 women). Analysis 1.10.
Maternal respiratory failure was reported in the Woman Trial
2017 with no clear evidence of difference between the randomised
groups (RR 0.87, 95% CI 0.67 to 1.12; 20,018 women). Analysis
1.11.
Similar numbers of women (approximately 1.1%) in both arms of
the trial suffered cardiac arrest (RR 0.95, 95% CI 0.73 to 1.23;
20,018 women). Analysis 1.12.
Renal failure was reported in both trials; the Ducloy-Bouthors
2011 trial reported no events, so estimable data are from the
Woman Trial 2017. There was little or no difference between
women receiving TXA versus placebo for this outcome, with ap-
proximately 1.3% and 1.2% of women in TXA and control arms
of the trial suffering renal failure (RR 1.09, 95% CI 0.85 to 1.39;
20,169 women). Analysis 1.13.
Similar numbers of women (29 versus 30) in the two arms of the
Woman Trial 2017 suffered hepatic failure (RR 0.96, 95% CI
0.58 to 1.60; 20,018 women). Analysis 1.14.
Maternal seizurewas reported in both trials contributing data but
all estimable data are from the Woman Trial 2017; the effect esti-
mate was imprecise with no clear evidence of differences between
groups (RR 0.76, 95% CI 0.49 to 1.20; 20,169 women). Analysis
1.15.
Ducloy-Bouthors 2011 reported maternal admission to inten-
sive care (ICU); 3/77 and 5/74 women in the TXA and control
group respectively were admitted to ICU (RR 0.58, 95% CI 0.14
to 2.33; 151 women). Analysis 1.16.
Secondary outcomes
Maternal mortality from causes other than bleeding
This outcome was reported in both trials; the Ducloy-Bouthors
2011 trial reported no events, so all estimable data are from the
Woman Trial 2017. There was no clear evidence of difference
between women receiving TXA versus placebo (RR 1.10, 95% CI
0.79 to 1.54; 20,172 women). Analysis 1.17.
(Non-prespecified) Maternal death or hysterectomy
(composite outcome)
This outcome was reported in the Woman Trial 2017; the risk of
death or hysterectomy was similar in both arms of the trial with
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approximately 5.4% of women experiencing this composite out-
come (RR 0.97, 95% CI 0.87 to 1.09; 20,017 women). Analysis
1.18.
Clinical shock and coagulopathy were not reported in either
trial.
Blood loss
Ducloy-Bouthors 2011 reported additional maternal blood loss
following randomisation (measured using a graduated pouch and
by weighing all swabs). Women receiving TXA versus usual care
alone may be at lower risk of blood loss of 500 mL or more
following randomisation (RR 0.50, 95% CI 0.27 to 0.93; 151
women; low-quality evidence). Analysis 1.19. For additional blood
loss of 1000 mL or more following randomisation there was
no clear difference between TXA and control groups as relatively
few women in either group (4/77 versus 8/74) experienced this
outcome (RR 0.48, 95% CI 0.15 to 1.53; 151 women). Analysis
1.20. Mean additional blood loss was also reported in Ducloy-
Bouthors 2011 and results showed blood loss in the TXA group
was on average approximately 100 mL less than in the control
group the 95% CI crossed the line of no effect (mean difference
(MD) -107.00 mL, 95% CI -224.44 to +10.44). Analysis 1.21.
Blood product transfusion
Although slightly fewer women in the TXA arm of the Ducloy-
Bouthors 2011 trial required a transfusion of blood or blood prod-
ucts, overall when pooled with results from theWoman Trial 2017
there was very little difference between groups with approximately
55% of women in both arms requiring transfusion (RR 1.00, 95%
CI 0.97 to 1.03; 20,167 women; I² = 55%,Tau² = 0.06; moderate-
quality evidence). (The I² value suggested moderate statistical het-
erogeneity for this outcome, which is probably explained by clin-
ical differences between the study participants and between study
settings, but as Tau² was low, and almost all of the data were con-
tributed by the Woman Trial 2017, we used a fixed-effect model.)
Analysis 1.22. For blood products transfusion, the Woman Trial
2017 showed very little difference between groups for transfusion
of frozen plasma or other products (RR 1.03, 95% CI 0.94 to
1.13, and RR 0.93, 95% CI 0.75 to 1.16, respectively). Analysis
1.23.
Additional uterotonics
The number of women receiving uterotonics (any) was reported
in both trials included in this comparison. In the Woman Trial
2017, the vast majority of women received these drugs post-ran-
domisation and similar numbers were described in the TXA and
placebo arms In the Ducloy-Bouthors 2011 trial, similar numbers
received post-randomisation uterotonics in the TXA and placebo
arms. Overall, pooled results showed that the use of uterotonics
was the same in the TXA and control groups (RR 1.00, 95%
CI 1.00 to 1.00; 20,162 women; studies = 2; I2 = 0%) Analysis
1.24. Trialists also reported comparisons by type of uterotonics
women received, and for all types reported (prostaglandins, oxy-
tocin, ergometrine and misoprostol), use in both arms of trials was
very similar (prostaglandins: RR 0.96, 95% CI 0.87 to 1.05; oxy-
tocin: RR 1.00, 95%CI 1.00 to 1.01; ergometrine: RR 1.00, 95%
CI 0.97 to 1.03; misoprostol: RR 0.99, 95% CI 0.97 to 1.01).
Analysis 1.25.
Maternal admission to a higher level of care was not reported
and nor was use of other haemostatic agents.
Surgical interventions to control bleeding
A range of surgical and invasive non-surgical interventions were
used to control bleeding.
Hysterectomy
In the Ducloy-Bouthors 2011, only one woman had an hysterec-
tomy, and overall, the number of women undergoing hysterec-
tomy (for any reason) was very similar in the TXA and placebo
arms of the Woman Trial 2017 (RR 1.01, 95% CI 0.88 to 1.17;
20,168 women); approximately 3.5% of women had an hysterec-
tomy. Analysis 1.26. The Woman Trial 2017 also reported the
number of women undergoing hysterectomy specifically to con-
trol bleeding, again, rates were very similar in the two groups (RR
0.95, 95%CI 0.81 to 1.12; 20,017 women, high-quality evidence).
Analysis 1.27.
There was no clear difference between groups for arterial ligation,
2.2% versus 2.5% undergoing this procedure in the TXA and
control groups (RR 0.88, 95% CI 0.74 to 1.05; 20,168 women).
Embolisation was infrequent, and there was no clear difference
between groups for this outcome (RR 0.82, 95% CI 0.42 to 1.62;
20,168 women). Late postpartum curettage was carried out in
three women in the Ducloy-Bouthors 2011 trial (RR 0.48, 95%
CI 0.04 to 5.19; 151 women). The use of intrauterine tamponade
was very similar in both arms of theWoman Trial 2017 (RR 0.96,
95% CI 0.87 to 1.06), as was manual removal of the placenta (RR
0.95, 95% CI 0.87 to 1.04; 20,017 women). Analysis 1.28.
In the Woman Trial 2017, the risk of laparotomy for bleeding
was lower in the TXA group (0.8% versus 1.3% in the placebo
group) (RR 0.64, 95% CI 0.49 to 0.85; 20,017 women), while
the risk of receiving brace sutures was increased (3% in the TXA
group versus 2.5% in controls) (RR 1.19, 95% CI 1.01 to 1.41;
participants = 20,017). Analysis 1.28.
Maternal vascular occlusive events
The number of women suffering vascular occlusive events was re-
ported in both trials. The Woman Trial 2017 reported the num-
ber of women having any vascular occlusive event (deep venous
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thrombosis (DVT), pulmonary embolism (PE), myocardial in-
farction (MI) or stroke); rates were very similar in women receiv-
ing either TXA or placebo (approximately 0.3% in each arm) (RR
0.88, 95% CI 0.54 to 1.43; 20,018 women, moderate-quality ev-
idence). Analysis 1.29.
For each type of vascular occlusive event, rates were generally very
low and there were no clear differences for these adverse events
between women receiving active treatment or placebo (DVT: RR
0.62, 95% CI 0.20 to 1.88; PE: RR 0.85, 95% CI 0.44 to 1.61;
MI: RR 0.66, 95% CI 0.11 to 3.97; stroke: RR 1.33, 95% CI
0.46 to 3.82) Analysis 1.30.
Other secondary outcomes were not reported (length of maternal
hospital stay, breastfeeding at hospital discharge, andmaternal
satisfaction with care).
Maternal quality of life at hospital discharge or after 42 days were
reported in the Woman Trial 2017. Quality of life was measured
using the EQ5D for five domains, and the number of women
reporting the worst scores for each domain was reported in the
trial report. There was no clear difference between groups for any
of the EQ5D domains reported (mobility: RR 0.96, 95%CI 0.58
to 1.58; self-care: RR 1.25, 95%CI 0.78 to 2.00; usual activities:
RR 0.86, 95% CI 0.56 to 1.32; pain and discomfort: RR 0.72,
95%CI 0.35 to 1.46; and, anxiety/depression: RR 1.03, 95%CI
0.62 to 1.71; 19,533). Overall rates of very poor quality of life for
each domain were low (approximately 0.3% or lower). Analysis
1.31; Analysis 1.32; Analysis 1.33; Analysis 1.34; Analysis 1.35.
Neonatal outcomes
The outcome,Vascular occlusive events in neonates was reported
in theWoman Trial 2017 but there were no events (Analysis 1.36).
Comparison 2 Tranexamic acid (TXA) versus rectal
misoprostol for the treatment of postpartum
haemorrhage (PPH)
A single study is included in this comparison and did not report
any of the review’s primary outcomes. Sahaf 2014 reported no
clear difference between intervention and control groups for mean
blood loss (MD 0.02 mL, 95% CI -0.09 to 0.13; 200 women).
Analysis 2.1.
D I S C U S S I O N
Summary of main results
Our main analysis includes data from two trials, one was a multi-
centre trial with a large sample size, and overall 20,212 woman
with postpartum haemorrhage (PPH) were recruited to these tri-
als. Both trials examined the use of tranexamic acid (TXA) to treat
PPH. Intravenous (IV) TXA when added to standard treatment
appears to reduce death from bleeding with an absolute reduction
in death from bleeding of four per 1000 and a relative reduction of
approximately 19% between the TXA and placebo groups (mod-
erate-quality evidence). The reduction in death due to bleeding was
primarily in women given treatment within three hours of giving
birth with no apparent reduction when given after three hours.
Maternal death from all causes was also reduced in the TXA group
although the 95% confidence interval crossed the line of no effect
for this outcome; the absolute reduction in death from all cause
was three per 1000 (from 25 per 1000 to 22 per 1000) (moderate-
quality evidence). There were no clear differences between groups
for some key outcomes; rates of any serious morbidity were sim-
ilar in intervention and control groups (high-quality evidence), as
were rates of hysterectomy to control bleeding (high-quality ev-
idence), need for blood or blood product transfusion (moderate-
quality evidence) or maternal vascular occlusive events (moderate-
quality evidence). Data from a trial with a small sample size suggest
additional maternal blood loss of 500 mL or more may be reduced
in women receiving TXA (low-quality evidence). There was an in-
crease in the use of brace sutures in the TXA group, whereas there
was a reduction in the need for laparotomy for bleeding in the
TXA treated group.
One study comparing TXA with rectal misoprostol reported on
only one outcome (mean blood loss) and identified no clear dif-
ference between groups.
Overall completeness and applicability of
evidence
We assessed the effect of antifibrinolytic drugs in women with
primary PPH. Of the four drugs included for evaluation in this
review (aprotinin, TXA, epsilon-aminocaproic acid (EACA) and
aminomethylbenzoic acid), only one (TXA) was evaluated in ran-
domised controlled trials (RCTs). We had also planned to examine
the effect of antifibrinolytics by route of administration (oral, IV,
intramuscular (IM) and buccal). However, included studies only
used the IV route. We had also planned to look at the effects of
interventions depending on the severity of haemorrhage at ran-
domisation (blood loss ≤ 1000 mL, > 1000 mL). We were un-
able to carry out this planned additional analyses as data were not
presented separately for women with less or more severe haemor-
rhage.
TXA was assessed in three included RCTs, of which only two pro-
vided data for the main analysis. A total of 20,172 women were
included in the two trials with over 99% from one trial. The trials
were conducted in high-, middle- and low-income settings. All
pre-specified primary outcomes were analysed (mortality due to
bleeding, all-cause mortality and serious maternal morbidity (re-
nal or respiratory failure, cardiac arrest or multiple organ failure)).
Also, side effects, specifically vascular occlusive events were anal-
ysed. There were no data on some secondary outcomes includ-
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ing shock, and coagulopathy. The large sample size of the pooled
studies suggest that the use of TXA when added to standard care
could reduce mortality from bleeding and overall mortality with-
out increasing the risk of vascular occlusive events. Although the
data showed that TXA reduced the number of women who had
blood loss of over 500 mL, the quality of this evidence was low.
Quality of the evidence
Two trials contributed data to the main comparison in the review.
One was a trial with a relatively small sample size comparing TXA
plus usual care with usual care alone; this trial was not blinded and
lack of blinding may have increased the risk of both performance
and detection bias (Ducloy-Bouthors 2011). The second trial had
a large sample size and was placebo-controlled and assessed as at
low risk of bias for all domains (Woman Trial 2017). For most
outcomes the vast majority of data were from the Woman Trial
2017.
For important outcomes we graded the evidence using Gradepro.
Some Grade decisions were difficult to assess. Most of the data
from the Woman Trial 2017 was from low- and middle-income
settings. We would not expect the biological effects of TXA for
women in different settings to vary. We did not downgrade for
indirectness. Inconsistency between trials was not an important
issue in this review as findings were dominated by a single trial.
Overall, evidence was mainly graded as moderate to high quality.
The main reason for downgrading evidence for some outcomes
was imprecision of effect estimates; even with a very large sample
size, with rare events such as maternal death, the 95% confidence
interval may suggest some uncertainty in findings.
Potential biases in the review process
We followed Cochrane methods to extract data and to assess risk
of bias and the certainty of the evidence. Two review authors in-
dependently extracted data, and a third review author examined
data extraction forms to identify any discrepancies between review
authors. The review team includes trialists involved in theWoman
Trial 2017. These review authors were not involved in data extrac-
tion or assessing risk of bias for this trial. However, review authors
involved in one of the included studies were involved in the se-
lection of outcomes and the interpretation of the data. Data entry
was double checked. Any discrepancies regarding assessment of
risk of bias or grading the evidence were resolved by discussion
within the team.
Agreements and disagreements with other
studies or reviews
There is evidence from systematic reviews that the antifibrinolytic
drug, TXA, reduces blood loss and the need for transfusion in
surgery (Henry 2011; McNicol 2016; Perel 2013). In our review,
although there was a reduction in blood loss in one small trial, we
did not see a reduction in the need for transfusion for the treat-
ment of PPH. TXA did not reduce the use of uterotonics, arterial
ligation, embolisation or hysterectomy. One explanation could be
that the decision about the need for these interventions is made
soon after the onset of PPH and before the trial intervention is
given or too soon for TXA to exert its effect. There was an increase
in the use of brace sutures in women who gave birth by caesarean
section, although the effect of TXA did not differ by mode of
giving birth. The review by Henry and colleagues showed a trend
towards reduction in the need for re-operation due to bleeding. In
our review, there was a significant reduction in the need for laparo-
tomy for bleeding.The results of a systematic review of antifibri-
nolytics for trauma, that are based largely on the CRASH-2 trial of
20,211 patients, showed that TXA reduces death due to bleeding
in trauma by a relative 15% (Ker 2015). In this review, we saw a
similar effect on death due to bleeding with a relative reduction of
19%. In trauma, treatment with TXA within one hour of injury
was associated with a 32% relative reduction in risk of death due
to bleeding, and treatment between one and three hours after in-
jury was associated with a 21% reduction. Treatment after three
hours of injury was associated with a 44% relative increase in risk
of death due to bleeding. In this review however, where women
received treatment with TXA between one and three hours after
birth, it was associated with a 40% relative reduction in risk of
death due to bleeding. For women who received treatment within
one hour of the birth, although we saw less deaths due to bleeding
in the treatment group, there were no clear differences between the
intervention and control groups. Where women were treated after
three hours, there was more deaths due to bleeding, but there was
no clear difference between the intervention and control groups.
However, there is no reason to believe that the biological action of
TXA would differ between bleeding trauma patients and women
with PPH. Indeed the results of a pre-specified analysis presented
in the finalWOMAN trial publication (Woman Trial 2017) shows
the consistency of the WOMAN results with the CRASH-2 re-
sults (Figure 4). Additionally, ameta-analysis of individual patient-
level data from 40 138 bleeding patients showed that deaths from
PPH peak at two to three hours after childbirth and every 15 min-
utes of treatment delay with TXA appears to decrease the benefit
by about 10%, with no benefit after three hours (Gayet-Ageron
2017). Taken together, the evidence from these trials strongly in-
dicates that treatment within three hours is themost effective. The
recently updated World Health Organization (WHO) guideline
on the use of TXA for the treatment of PPH recommends that
TXA is given as soon as possible to achieve clinical benefits as most
deaths due to PPH occur within the first two to three hours after
birth and did not support the use of TXA more than three hours
after birth (WHO 2017).
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Figure 4. Time to treatment. Effect of TXA on death due to bleeding by time to treatment in the WOMAN
and CRASH-2 trials (reproduced from http://dx.doi.org/10.1016/S0140-6736(17)30638-4)
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The use of the antifibrinolytic drug tranexamic acid (TXA) appears
to reduce the risk of death due to bleeding without increasing
the risk of vascular occlusive events. There is evidence from this
review and from another major trial that the effect on death due
to bleeding depends on the time interval between giving birth
and the commencement of treatment, and this would suggest that
TXA should be given as early as possible and within three hours
of giving birth.
Implications for research
Our review found data for only the antifibrinolytic drug, TXA; we
did not identify trials examining the use of other antifibrinolytic
drugs. As the use of the antifibrinolytic aprotinin in other bleeding
conditions is controversial, trials of this agent in the treatment of
postpartum haemorrhage (PPH) are unlikely in the near future.
We identified that only intravenous administration of TXA was
evaluated. Many women die from PPH, having delivered at home
or in facilities in resource-poor settings where intravenous drugs
cannot be administered, there is urgent need for trials of alternative
routes of administration.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ducloy-Bouthors 2011
Methods Parallel RCT.
Participants Setting: 8 obstetric units, France.
Dates of recruitment: 2005 to 2008.
152 women randomised.
Inclusion criteria: women with PPH > 800 mL within 2 hours after vaginal delivery
Exclusion criteria: age < 18 years, no informed consent, caesarean section, known
haemostatic abnormality, history of thrombosis or epilepsy
Interventions Experimental intervention: loading dose of 4 g TXA mixed with 50 mL saline, admin-
istered intravenously over 1 hour followed by maintenance dose of 1 g/hour for 6 hours
(n = 78)
Control/Comparison intervention: no TXA (n = 74).
Outcomes Primary outcome: volume of blood loss between inclusion (T1) and after 6 hours (T4)
Secondary outcomes: duration of bleeding; anaemia; need for invasive procedures; need
for transfusion; major thrombotic events, renal failure, seizures; minor side effects
Notes Funding: French Ministry of Health.
Conflict of interest: “The authors declare that they have no competing interests”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation sequence was generated by a centralized
computer, and randomisation was balanced by centre.”
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk All outcomes: “Although the study was not blinded, obstetrician
and midwives were not aware of the treatment group, so the rest
of the management, blood loss measurement and transfusion
algorithm were conducted regardless of the group allocation”
However, as the treatment group would have an IV infusion
ongoing for 7 hours and control group none, it would be difficult
to blind in this situation. No explanation given as to how this
was achieved
Blood loss outcome: “Midwives unaware of the group allocation
measure the volume of haemorrhage in the graduated collection
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Ducloy-Bouthors 2011 (Continued)
bag at each time point”
However, as the treatment group would have an IV infusion
ongoing for 7 hours and control group none, it would be difficult
to blind in this situation. No explanation given as to how this
was achieved
Death: ascertainment of death would be unlikely to be biased
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman assigned to TXA was later found not to be eligible and
was excluded from ITT analysis
Selective reporting (reporting bias) Unclear risk Retrospectively registered. Unable to compare reported results
to pre-specified outcomes
Other bias Low risk Other bias not apparent.
Sahaf 2014
Methods Described as double-blind randomised trial in Tabriz, Iran.
Participants 200 women after caesarean or vaginal birth with PPH (500mL to 1500 mL) after routine
therapies for controlling bleeding
Study conducted between June 2011 and June 2013.
Interventions 1 g IV TXA repeated after 30 minutes versus 5 200 micrograms rectal misoprostol.
Prostatglandin F2 in case of treatment failure in both groups
Outcomes Estimation of blood loss (weighing sponges).
Notes There was no information about how women were randomised. There was limited
information on results
Funding: Trial reported stated “nil” under source of funding
Conflict of interest: Trial report stated “none declared”.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Divided into “two equal groups” using
computer software.
Allocation concealment (selection bias) Unclear risk No information (2 equal groups).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
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Sahaf 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It was not clear if there was any loss to
follow-up or missing data. 2 equal-sized
groups
Selective reporting (reporting bias) Unclear risk Protocol registered retrospectively.
Other bias Unclear risk Some differences between groups at base-
line in terms of episiotomy andperineal lac-
eration
Woman Trial 2017
Methods Randomised, double-blind, placebo-controlled trial.
Participants Number randomised: 20,060 women recruited and randomised
Setting: 193 hospitals or maternal health facilities from 21 high-, middle- or low-income
countries in which women have delivered their babies or were secondary hospitalised
after delivery due to a diagnosis of PPH (recruitment in high-income countries: UK:
569 women; recruitment in low- and middle-income countries: Nigeria: 5711; Pakistan:
5282; Uganda: 2235; Kenya: 1031; Cameroon: 893; Sudan: 860; Tanzania: 538; Nepal:
533; Zambia: 496; Albania: 485; Democratic Republic of Congo: 457; Bangladesh: 325;
Ethiopia: 302; Burkina Faso: 142; Jamaica: 73; Ghana: 41; Papua New Guinea: 38;
Egypt: 33; Colombia: 8; Cote d’Ivoire: 8). Dates of recruitment: March 2010 to April
2016
Inclusion criteria:
• Legally adult women (aged 16 years or older).
• With clinically diagnosed PPH (estimated blood loss after vaginal delivery of a
baby > 500 mL OR > 1000 mL from caesarean section OR estimated blood loss
enough to compromise the haemodynamic status of the woman) following vaginal
delivery of a baby or caesarean section.
• Women who have delivered their babies at a participating hospital or outside a
participating hospital, with hospital admission following delivery.
• Responsible clinician is substantially uncertain as to whether or not to use TXA.
• Consent has been given following approved procedures.
Exclusion criteria:
• Women for whom the responsible clinician considers there is a clear indication for
TXA.
• Women for whom the responsible clinician considers there is a clear
contraindication for TXA use (e.g. a known thromboembolic event during pregnancy).
• If the responsible clinician is certain about the use or the non use of TXA.
• Women recruited to the trial received all usual care but were also randomly
allocated to receive TXA or placebo.
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Woman Trial 2017 (Continued)
Interventions Experimental intervention
First dose: IV TXA 2 ampoules = 1 g at approximate rate of 1 mL/minute as soon after
randomisation followed by second dose of 2 ampoules = 1 g (at approximate rate of 1
mL/minute) if after 30 minutes bleeding continues or if it stops and restarts within the
24 hours after the first dose. Clinicians advised that the trial treatment should not be
mixed with blood for transfusion or infusion solutions containing penicillin or mannitol
Each treatment pack contained 4 x 500 mg ampoules of TXA, 2 x sterile 10 mL syringe
and 21 FG needle and stickers for attaching to data forms and patient medical records
(n = 10,051)
Control intervention: placebo (sodium chloride 0.9% contained in ampoules and pack-
aging with identical appearance). Same regimen and identical packs as those used in the
experimental group (n = 10,009)
Outcomes Outcomes:
(measured at hospital discharge or on day 42 if still in hospital)
Primary outcome: composite of death from all causes or hysterectomy within 42 days
of randomisation
(Participating clinicians were requested to record the immediate cause of death (the final
pathophysiological process leading to death) rather than the underlying cause of death
and were trained accordingly. In the event that there was more than 1 cause, clinicians
were asked to record the main cause.)
Secondary outcomes:
• Death was assessed separately and immediate main cause of death was also
recorded (final pathophysiological process leading to death), death due to bleeding
considered as secondary outcome.
• Vascular occlusive events (deep-vein thrombosis, pulmonary embolism,
myocardial infarction and stroke).
• Surgical Interventions including intrauterine tamponade; embolisation; brace
suture (B-Lynch/Cho); artery ligation, to achieve haemostasis; hysterectomy and
laparotomy done after randomisation to control bleeding.
• Complications (renal failure, cardiac failure, respiratory failure, hepatic failure,
sepsis and seizures).
• Other untoward medical events (adverse events).
• Quality of life measured using EQ5D at discharge from the randomising hospital
or in hospital at 42 days after randomisation.
• Status of any vascular occlusive events in breastfed babies assessed as per normal
clinical practice with no special tests done.
Other outcomes reported in the protocol published in 2010 and not listed in final
publication:
• Medical events including adult respiratory distress syndrome, hypertensive
disorders of pregnancy (including HELLP Syndrome, eclampsia, toxaemia of
pregnancy) and other adverse events reported.
• Length of stay at hospital/time spent at an intensive care unit.
• Receipt of mechanical ventilation.
Notes The sample size was increased from 15,000 to 20,000 woman as the trial was ongoing
to allow for sufficient power to detect a reduction in maternal mortality alone
Funding: London School of Hygiene & Tropical Medicine, Pfizer, UK Department of
Health, Wellcome Trust, and Bill & Melinda Gates Foundation
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Woman Trial 2017 (Continued)
Conflict of interest: the trial report stated that there were no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was generated and secured
by an independent statistical consultant
fromSealed Envelope Ltd (UK). The codes
were then made available to Brecon Phar-
maceuticals Limited (UK) explicitly for the
treatment packs to be created in accordance
with the randomisation list
Allocation concealment (selection bias) Low risk After eligibility was confirmed and con-
sent procedures completed, baseline infor-
mation was collected on the entry form.
Women were then randomly allocated to
TXA or placebo group by selection of
the lowest numbered treatment pack form
from a box containing eight numbered
packs that were identical apart from the
pack number. (An emergency un-blinding
service was available from the pharmaceu-
tical company.)
(No information was provided in the trial
report re any verification of whether se-
quence order was followed or whether any
packs were not used.)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All outcomes: use of TXA versus placebo
with ampoules and packaging identical in
appearance
Participants, caregivers and study staff (site
investigators and trial co-ordinating centre
staff ) were blinded to treatment allocation
The masking was done by Brecon Pharma-
ceuticals Limited, Hereford, UK and in-
volved the removal of the original manu-
facturer’s label and replacement with the
clinical trial label bearing the randomisa-
tion number, which was used as the pack
identification. Apart from the randomisa-
tion number, all pack label texts were iden-
tical forTXAandplacebo.Correctmasking
and coding of ampoules was checked by in-
dependent random testing of each batch by
high-performance liquid chromatography
to confirm the contents of the ampoules
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Woman Trial 2017 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcomesweremeasured at hospital dis-
charge or on day 42 if still in hospital. Data
were sent to the trial co-ordinating centre
by direct entry into an electronic database
or by using encrypted data forms (which
were sent by fax, email, or uploaded to a
secure server). Data quality was monitored
using a combination of centralised consent
monitoring, statistical data checking, and
site visits at which patient data forms were
compared with clinical case notes
Death is an objective outcome that could
not be “manipulated”. Cause of death is
more subject to be influencedby the knowl-
edge of intervention received but treatment
allocation group was blinded so the risk is
low
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 women withdrew their consent after ran-
domisation and data were excluded from
the analyses (4 in the TXA group and 3 in
the placebo group)
32 women did not have primary outcome
data (11 in active group and 21 in control
group) and were thus excluded from anal-
yses
Reasons for incompleteness were not de-
scribed in the trial report. However, overall
there were only small numbers missing so
unlikely to impact on results
Selective reporting (reporting bias) Low risk Most outcomes pre-specified in the proto-
col were reported in final publication ex-
cept length of hospital stay and receipt of
mechanical ventilation
Primary outcome: composite of death from
all causes or hysterectomy within 42 days
of randomisation
Other bias Low risk No other risk of bias identified.
HELLP: haemolysis, elevated liver enzymes, low platelet count
ITT: intention-to-treat
IV: intravenous
PPH: postpartum haemorrhage
RCT: randomised controlled trial
TXA: tranexamic acid
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahonen 2013 This trial looks at treatment for women with severe PPH. It examines prothrombin complex plus fibrinogen
versus fresh frozen plasma plus fibrinogen if needed. This comparison is not relevant for this review which
focuses on antifibrinolytic drugs
Bruynseels 2016 This trial looks at treatment for women with severe PPH. It examines fibrinogen concentrate versus placebo.
This comparison is not relevant for this review which focuses on antifibrinolytic drugs
Ducloy-Bouthors 2016 This ongoing trial looks at treatment for women with severe PPH. It examines fibrinogen versus placebo.
This comparison is not relevant for this review which focuses on antifibrinolytic drugs
Lavigne-Lissalde 2015 This trial looks at treatment for women with PPH unresponsive to uterotonics. It examines an infusion of
recombinant human factor VIIa versus usual care. This comparison is not relevant for this review which
focuses on antifibrinolytic drugs
Paidas 2015 This ongoing trial looks at treatment for women with PPH and low fibrinogen levels. It examines fibrinogen
concentrate versus placebo. This comparison is not relevant for this review which focuses on antifibrinolytic
drugs
Sadeghipour 2013 This study was not clearly about PPH but about the treatment of uterine atony
von Beckerath 2016 This is a comparison of a topical mechanical agent versus amechanical device to treat PPH.This comparison
is not relevant for this review which focuses on antifibrinolytic drugs
Wikkelso 2015 This trial looks at treatment for women with severe PPH. It examines fibrinogen concentrate versus placebo.
This comparison is not relevant for this review which focuses on antifibrinolytic drugs
Wiznitzer 2011 The intervention in this study is a dressing for vaginal tears; there was no evidence from the trial registration
that women had PPH
PPH: postpartum haemorrhage
Characteristics of studies awaiting assessment [ordered by study ID]
Ayedi 2011
Methods Described as a prospective randomised double-blind placebo-controlled trial
Participants 74 women following caesarean section with spinal anaesthesia with postpartum bleeding due to uterine atony not
controlled by oxytocin
Inclusion criteria: women aged 20-40 years with uterine atony receiving sulprostone
Exclusion: women with abnormal placentation, severe pre-eclampsia, coagulopathy or uterine rupture. Women with
contraindication to tranexamic acid. Women with accidental surgical complications (e.g. bladder or colon damage)
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Ayedi 2011 (Continued)
were not included
Interventions Women were divided into 2 groups of 37 women.
Tranexamic acid group: 10 mg/kg of tranexamic acid within 12 minutes as an induction dose, followed by a main-
tenance dose 1 mg/kg/hour during the following 2 hours
Control: placebo with same volumes from identical 20 mL syringes
Outcomes Blood loss, blood transfusions, deep vein thrombosis, hysterectomy
Notes Results from this study are reported in a brief abstract and in an unpublished manuscript. There was no information
about how women were randomised. There was limited information on results. We have tried to contact the author.
If further information is available for the next update we will reassess this study for inclusion
Characteristics of ongoing studies [ordered by study ID]
Sambou 2015
Trial name or title Tranexamic acid to reduce blood loss in hemorrhagic caesarean delivery: a multicenter randomised double
blind placebo controlled dose ranging study - TRACES
Methods Multicentre randomised double-blind placebo-control therapeutic and pharmaco-biological dose-ranging
study
Participants Inclusion criteria:
Women:
• Experiencing a bleeding volume of more than 800 mL
• Due to surgery or to atony uterine
• During an elective or non-emergeny caesarean section
• After complete information and consent signature
• Covered by social security. Reference non-haemorrhagic group
Exclusion criteria:
Women unable to consent (< 18 years old or incapable people and specially protected mentioned in the article
L1121-5 to L1121-8) RCP medical contraindication to TXA acid such as
• Hypersensibility to the product or excipient
• Previous or ongoing arterial or venous thrombosis
• Coagulopathy, except DIC associated with a predominant fibrinolytic profile
• Renal failure
• Previous seizures
• Intrathecal or intraventricular administration. Obstetrical contraindication to TXA
• Severe HELLP syndrome (platelet count < 50,000/m3 or renal failure prior to the caesarean. Protocol-
related contraindication to inclusion
• Emergent caesarean section
• Administration of TXA before inclusion
• Inherited haemorrhagic diseases or low molecular weight heparin within 24 hours before inclusion
• Previous inclusion in an interventional trial since the 2 months before caesarean section
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Sambou 2015 (Continued)
Interventions Experimental: TXA 1 g or TXA 0.5 g intravenous as bolus over 1 minute
Control: placebo (saline).
Outcomes Primary outcome measures: bleeding between inclusion and 6 hours after inclusion
Secondary outcomes:
• Postpartum anaemia (days 2 and 5)
• Postpartum blood loss (day 2)
• Maternal morbidity i.e. haemostatic interventions and organ failure and intensive care unit admission
up to 42 days
• Death up to 42 days
• Biological fibrinolysis inhibition (percentage of women for which D Dimers increase is blunted)
• Urinary urea and creatinuria on timed diuresis
• The number of women developing an oliguria or a renal failure
• Deep vein thrombosis or pulmonary embolism
• Visual disturbances
• Nausea
• Peak plasma concentration (Cmax) in venous blood
• Area under the plasma concentration versus time curve (AUC) in venous blood
• Lagtime between thrombin and plasmin peaks (s) in venous blood
• Peak plasma concentration (Cmax) in uterine bleeding
• Area under the plasma concentration versus time curve (AUC) in uterine bleeding
• Lagtime between thrombin and plasmin peaks (s) in uterine bleeding
• TXA plasma concentration
• TXA urinary excretion
Starting date March 2016. Final data collection February 2018.
Contact information Anne-Sophie Ducloy-Bouthors, MD; anne-sophie.ducloy@chru-lille.fr
Hospital Jeanne de Flandre - CHRU de Lille, France.
Notes Sponsor: University Hospital, Lille.
ClinicalTrials.gov identifier: NCT02797119
Winikoff 2016
Trial name or title Effectiveness of tranexamic acid when used as an adjunct to misoprostol for the treatment of postpartum
haemorrhage
Methods This study is a randomised, double-blind, placebo-controlled trial that will enrol 250 women (125 per study
arm). Phase 4 trial
Participants The objective of the study is to determine the efficacy and tolerability of oral TXA when used as an adjunct
to misoprostol for treatment of postpartum haemorrhage. Women will be diagnosed with postpartum haem-
orrhage if blood loss reaches 700 mL in the calibrated receptacle
Inclusion criteria:
• Women who delivery vaginally
• Women who experience postpartum haemorrhage defined as blood loss ≥ 700 mL
• Women capable of giving consent
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Winikoff 2016 (Continued)
Exclusion criteria:
• Clear contraindication for TXA such as known allergy or thromboembolic event during pregnancy
• Women delivering via caesarean section
• Provider feels that the woman, at presentation for delivery, is not in a position to give appropriate
informed consent
Interventions Women diagnosed with postpartum haemorrhage will be randomised to receive either TXA or placebo, both
in tablet form. All participants will receive 800 mcg sublingual misoprostol (4 tablets 200 mcg each)
Outcomes Primary: proportion of women with bleeding controlled with the study regimens alone, without recourse to
further treatment
Secondary: rate of severe postpartum haemorrhage (> 1000 mL total blood loss); mean/median blood loss;
proportionofwomenwith bleeding controlled at different time intervals (20, 40, 60, 120minutes); proportion
of women who are given uterotonic agents after initial treatment; serious intervention (defined as blood
transfusion, interventions for tissue repair, surgical intervention (including curettage, vacuum aspiration for
retained placental tissue, hysterectomy, surgical uterine artery ligature)); proportion of women who receive
additional drugs; proportion of women who receive additional interventions (i.e. suturing); proportion of
women who experience an adverse event; proportion of women who experience side effects; proportion of
women who find the procedure tolerable and acceptable as indicated in an acceptability scale
Starting date October 2016. Final data collection October 2017.
Contact information Centre hospitalier Abass Ndao, Dakar, Sengal. Contact: Marie Antoinette Cmara +221 775376984
Centre hospitalier Regional de Thies, Senegal. Contact: Rachel Sarr +221 776086090
Hung Vuong Hospital, Ho Chi Minh City, Vietnam. Contact: Nguyen Thi Nhu Ngog, MD
Principal Investigator: Beverly Winikoff, Gynuity Health Projects
Notes Sponsored by Gynuity Health Projects.
DIC: disseminated intravascular coagulation
HELLP: haemolysis, elevated liver enzymes, low platelet count
TXA: tranexamic acid
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D A T A A N D A N A L Y S E S
Comparison 1. Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of
PPH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality due to
bleeding
2 20172 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.65, 1.00]
2 Maternal mortality due to
bleeding (subgroup by mode of
birth)
1 20014 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
2.1 Vaginal delivery 1 14191 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.64, 1.05]
2.2 Caesarean 1 5823 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.54, 1.18]
3 Maternal mortality due to
bleeding (subgroup time from
birth)
1 20011 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.66, 1.01]
3.1 Less than 1 hour 1 9572 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.55, 1.16]
3.2 1-3 hours 1 5356 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.41, 0.88]
3.3 More than 3 hours 1 5083 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.76, 1.51]
4 Maternal mortality (all causes) 2 20172 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.05]
5 Maternal mortality (all
cause)(subgroup by mode of
birth)
1 20016 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.06]
5.1 Vaginal delivery 1 14191 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.69, 1.07]
5.2 Caesarean 1 5825 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.68, 1.26]
6 Maternal mortality (all cause)
(subgroup time from birth)
1 20011 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.75, 1.06]
6.1 Less than 1 hour 1 9572 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.72, 1.33]
6.2 1-3 hours 1 5356 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.49, 0.96]
6.3 More than 3 hours 1 5083 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.75, 1.33]
7 Serious maternal morbidity (any) 1 20015 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.19]
8 Serious maternal morbidity (any)
(subgroup by mode of birth)
1 20013 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.82, 1.19]
8.1 Vaginal birth 1 14189 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.77, 1.21]
8.2 Caesarean 1 5824 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.76, 1.44]
9 Serious maternal morbidity
(any) (subgroup by time of
drug use from birth)
1 20007 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.83, 1.20]
9.1 Drug intake < 1 hour 1 9570 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.55]
9.2 Drug intake 1-3 hours 1 5354 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.62, 1.21]
9.3 Drug intake > 3 hours 1 5083 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.75, 1.36]
10 Serious maternal morbidity:
multiple organ failure
2 20168 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.71, 1.23]
11 Serious maternal morbidity:
maternal respiratory failure
1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.67, 1.12]
12 Serious maternal morbidity:
Cardiac arrest
1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.73, 1.23]
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13 Serious maternal morbidity:
Maternal renal failure
2 20169 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.85, 1.39]
14 Serious maternal morbidity:
Hepatic failure
1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.58, 1.60]
15 Serious maternal morbidity:
Maternal Seizure
2 20169 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.49, 1.20]
16 Maternal Intensive care
admission
1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.14, 2.33]
17 Mortality from causes other
than bleeding
2 20172 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.79, 1.54]
18 Non-prespecified composite
outcome: death or
hysterectomy
1 20017 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.09]
19 Blood loss 500 mL or more
after randomisation
1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.27, 0.93]
20 Blood loss 1000 mL or more
after randomisation
1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.15, 1.53]
21 Mean blood loss (mL) 1 151 Mean Difference (IV, Fixed, 95% CI) -107.0 [-224.44, 10.
44]
22 Blood transfusion (all) 2 20167 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.97, 1.03]
23 Blood products transfusion 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 Frozen plasma 1 20013 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.94, 1.13]
23.2 Other product
transfusion
1 20013 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.75, 1.16]
23.3 Any transfusion 1 19916 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.97, 1.02]
24 Post randomisation additional
uterotonics
2 20162 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [1.00, 1.00]
25 Post randomisation additional
uterotonics
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
25.1 Prostaglandin 2 20162 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.87, 1.05]
25.2 Oxytocin 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [1.00, 1.01]
25.3 Ergometrine 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.97, 1.03]
25.4 Misoprostol 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.97, 1.01]
26 Hysterectomy (provided it is
not part of the intervention
under investigation)
2 20168 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.88, 1.17]
27 Hysterectomy to control
bleeding
1 20017 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.81, 1.12]
28 Post randomisation surgical
intervention to control
bleeding
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
28.1 Arterial ligation 2 20168 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.05]
28.2 Embolisation 2 20168 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.42, 1.62]
28.3 Late postpartum
curettage (after day 7)
1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.19]
28.4 Intrauterine tamponade 1 20017 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.87, 1.06]
28.5 Manual removal of
placenta
1 20017 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.87, 1.04]
28.6 Laparotomy for bleeding 1 20017 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.85]
28.7 Brace sutures 1 20017 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.01, 1.41]
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29 Side effects of the intervention:
any maternal vascular occlusive
event
1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.54, 1.43]
30 Side effects of the intervention:
maternal vascular occlusive
events
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
30.1 DVT 2 20169 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.20, 1.88]
30.2 Pulmonary embolism 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.61]
30.3 Myocardial infarction 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 3.97]
30.4 Stroke 1 20018 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.46, 3.82]
31 Quality of Life: EQ5D
Mobility
1 19533 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.58, 1.58]
32 Quality of Life: EQ5D Self care 1 19533 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.78, 2.00]
33 Quality of Life: EQ5D Usual
activities
1 19533 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.32]
34 Quality of Life: EQ5D
Pain/discomfort
1 19533 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.35, 1.46]
35 Quality of Life: EQ5D
Anxiety/depression
1 19533 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.62, 1.71]
36 Side effects of the intervention:
neonatal vascular occlusive
event
1 20018 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Tranexamic acid versus rectal misoprostol for the treatment of PPH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean blood loss (mL) 1 200 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.09, 0.13]
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Analysis 1.1. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 1 Maternal mortality due to bleeding.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 1 Maternal mortality due to bleeding
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 155/10036 191/9985 100.0 % 0.81 [ 0.65, 1.00 ]
Total (95% CI) 10113 10059 100.0 % 0.81 [ 0.65, 1.00 ]
Total events: 155 (Tranexamic acid), 191 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.2. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 2 Maternal mortality due to bleeding (subgroup by mode of birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 2 Maternal mortality due to bleeding (subgroup by mode of birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal delivery
Woman Trial 2017 110/7083 135/7108 70.7 % 0.82 [ 0.64, 1.05 ]
Subtotal (95% CI) 7083 7108 70.7 % 0.82 [ 0.64, 1.05 ]
Total events: 110 (Tranexamic acid), 135 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
2 Caesarean
Woman Trial 2017 45/2952 55/2871 29.3 % 0.80 [ 0.54, 1.18 ]
Subtotal (95% CI) 2952 2871 29.3 % 0.80 [ 0.54, 1.18 ]
Total events: 45 (Tranexamic acid), 55 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 10035 9979 100.0 % 0.81 [ 0.66, 1.00 ]
Total events: 155 (Tranexamic acid), 190 (Placebo/std care)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.5 0.7 1 1.5 2
Favours tranexamic acid Favours placebo/std care
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Analysis 1.3. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 3 Maternal mortality due to bleeding (subgroup time from birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 3 Maternal mortality due to bleeding (subgroup time from birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than 1 hour
Woman Trial 2017 49/4846 60/4726 32.0 % 0.80 [ 0.55, 1.16 ]
Subtotal (95% CI) 4846 4726 32.0 % 0.80 [ 0.55, 1.16 ]
Total events: 49 (Tranexamic acid), 60 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 1-3 hours
Woman Trial 2017 40/2674 67/2682 35.2 % 0.60 [ 0.41, 0.88 ]
Subtotal (95% CI) 2674 2682 35.2 % 0.60 [ 0.41, 0.88 ]
Total events: 40 (Tranexamic acid), 67 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0096)
3 More than 3 hours
Woman Trial 2017 66/2514 63/2569 32.8 % 1.07 [ 0.76, 1.51 ]
Subtotal (95% CI) 2514 2569 32.8 % 1.07 [ 0.76, 1.51 ]
Total events: 66 (Tranexamic acid), 63 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 10034 9977 100.0 % 0.82 [ 0.66, 1.01 ]
Total events: 155 (Tranexamic acid), 190 (Placebo/std care)
Heterogeneity: Chi2 = 4.90, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 4.90, df = 2 (P = 0.09), I2 =59%
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.4. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 4 Maternal mortality (all causes).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 4 Maternal mortality (all causes)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 227/10036 256/9985 100.0 % 0.88 [ 0.74, 1.05 ]
Total (95% CI) 10113 10059 100.0 % 0.88 [ 0.74, 1.05 ]
Total events: 227 (Tranexamic acid), 256 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.5. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 5 Maternal mortality (all cause)(subgroup by mode of birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 5 Maternal mortality (all cause)(subgroup by mode of birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal delivery
Woman Trial 2017 148/7083 172/7108 67.1 % 0.86 [ 0.69, 1.07 ]
Subtotal (95% CI) 7083 7108 67.1 % 0.86 [ 0.69, 1.07 ]
Total events: 148 (Tranexamic acid), 172 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Caesarean
Woman Trial 2017 79/2952 83/2873 32.9 % 0.93 [ 0.68, 1.26 ]
Subtotal (95% CI) 2952 2873 32.9 % 0.93 [ 0.68, 1.26 ]
Total events: 79 (Tranexamic acid), 83 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 10035 9981 100.0 % 0.88 [ 0.74, 1.06 ]
Total events: 227 (Tranexamic acid), 255 (Placebo/std care)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 1.6. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 6 Maternal mortality (all cause) (subgroup time from birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 6 Maternal mortality (all cause) (subgroup time from birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Less than 1 hour
Woman Trial 2017 80/4846 80/4726 31.8 % 0.98 [ 0.72, 1.33 ]
Subtotal (95% CI) 4846 4726 31.8 % 0.98 [ 0.72, 1.33 ]
Total events: 80 (Tranexamic acid), 80 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 1-3 hours
Woman Trial 2017 57/2674 83/2682 32.5 % 0.69 [ 0.49, 0.96 ]
Subtotal (95% CI) 2674 2682 32.5 % 0.69 [ 0.49, 0.96 ]
Total events: 57 (Tranexamic acid), 83 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
3 More than 3 hours
Woman Trial 2017 90/2514 92/2569 35.7 % 1.00 [ 0.75, 1.33 ]
Subtotal (95% CI) 2514 2569 35.7 % 1.00 [ 0.75, 1.33 ]
Total events: 90 (Tranexamic acid), 92 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 10034 9977 100.0 % 0.89 [ 0.75, 1.06 ]
Total events: 227 (Tranexamic acid), 255 (Placebo/std care)
Heterogeneity: Chi2 = 3.25, df = 2 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 3.25, df = 2 (P = 0.20), I2 =39%
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Analysis 1.7. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 7 Serious maternal morbidity (any).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 7 Serious maternal morbidity (any)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 223/10030 224/9985 100.0 % 0.99 [ 0.83, 1.19 ]
Total (95% CI) 10030 9985 100.0 % 0.99 [ 0.83, 1.19 ]
Total events: 223 (Tranexamic acid), 224 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 8 Serious maternal morbidity (any) (subgroup by mode of birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 8 Serious maternal morbidity (any) (subgroup by mode of birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vaginal birth
Woman Trial 2017 148/7081 154/7108 68.4 % 0.96 [ 0.77, 1.21 ]
Subtotal (95% CI) 7081 7108 68.4 % 0.96 [ 0.77, 1.21 ]
Total events: 148 (Tranexamic acid), 154 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
2 Caesarean
Woman Trial 2017 75/2951 70/2873 31.6 % 1.04 [ 0.76, 1.44 ]
Subtotal (95% CI) 2951 2873 31.6 % 1.04 [ 0.76, 1.44 ]
Total events: 75 (Tranexamic acid), 70 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 10032 9981 100.0 % 0.99 [ 0.82, 1.19 ]
Total events: 223 (Tranexamic acid), 224 (Placebo/std care)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 1.9. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 9 Serious maternal morbidity (any) (subgroup by time of drug use from
birth).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 9 Serious maternal morbidity (any) (subgroup by time of drug use from birth)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Drug intake < 1 hour
Woman Trial 2017 78/4844 68/4726 30.8 % 1.12 [ 0.81, 1.55 ]
Subtotal (95% CI) 4844 4726 30.8 % 1.12 [ 0.81, 1.55 ]
Total events: 78 (Tranexamic acid), 68 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 Drug intake 1-3 hours
Woman Trial 2017 62/2672 72/2682 32.1 % 0.86 [ 0.62, 1.21 ]
Subtotal (95% CI) 2672 2682 32.1 % 0.86 [ 0.62, 1.21 ]
Total events: 62 (Tranexamic acid), 72 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
3 Drug intake > 3 hours
Woman Trial 2017 83/2514 84/2569 37.1 % 1.01 [ 0.75, 1.36 ]
Subtotal (95% CI) 2514 2569 37.1 % 1.01 [ 0.75, 1.36 ]
Total events: 83 (Tranexamic acid), 84 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 10030 9977 100.0 % 1.00 [ 0.83, 1.20 ]
Total events: 223 (Tranexamic acid), 224 (Placebo/std care)
Heterogeneity: Chi2 = 1.20, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 1.20, df = 2 (P = 0.55), I2 =0.0%
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Analysis 1.10. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 10 Serious maternal morbidity: multiple organ failure.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 10 Serious maternal morbidity: multiple organ failure
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 99/10032 105/9985 100.0 % 0.94 [ 0.71, 1.23 ]
Total (95% CI) 10109 10059 100.0 % 0.94 [ 0.71, 1.23 ]
Total events: 99 (Tranexamic acid), 105 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 11 Serious maternal morbidity: maternal respiratory failure.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 11 Serious maternal morbidity: maternal respiratory failure
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 108/10033 124/9985 100.0 % 0.87 [ 0.67, 1.12 ]
Total (95% CI) 10033 9985 100.0 % 0.87 [ 0.67, 1.12 ]
Total events: 108 (Tranexamic acid), 124 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 12 Serious maternal morbidity: Cardiac arrest.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 12 Serious maternal morbidity: Cardiac arrest
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 110/10033 115/9985 100.0 % 0.95 [ 0.73, 1.23 ]
Total (95% CI) 10033 9985 100.0 % 0.95 [ 0.73, 1.23 ]
Total events: 110 (Tranexamic acid), 115 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 13 Serious maternal morbidity: Maternal renal failure.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 13 Serious maternal morbidity: Maternal renal failure
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 129/10033 118/9985 100.0 % 1.09 [ 0.85, 1.39 ]
Total (95% CI) 10110 10059 100.0 % 1.09 [ 0.85, 1.39 ]
Total events: 129 (Tranexamic acid), 118 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 14 Serious maternal morbidity: Hepatic failure.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 14 Serious maternal morbidity: Hepatic failure
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 29/10033 30/9985 100.0 % 0.96 [ 0.58, 1.60 ]
Total (95% CI) 10033 9985 100.0 % 0.96 [ 0.58, 1.60 ]
Total events: 29 (Tranexamic acid), 30 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 15 Serious maternal morbidity: Maternal Seizure.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 15 Serious maternal morbidity: Maternal Seizure
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 33/10033 43/9985 100.0 % 0.76 [ 0.49, 1.20 ]
Total (95% CI) 10110 10059 100.0 % 0.76 [ 0.49, 1.20 ]
Total events: 33 (Tranexamic acid), 43 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 16 Maternal Intensive care admission.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 16 Maternal Intensive care admission
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 3/77 5/74 100.0 % 0.58 [ 0.14, 2.33 ]
Total (95% CI) 77 74 100.0 % 0.58 [ 0.14, 2.33 ]
Total events: 3 (Tranexamic acid), 5 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 17 Mortality from causes other than bleeding.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 17 Mortality from causes other than bleeding
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 0/74 Not estimable
Woman Trial 2017 72/10036 65/9985 100.0 % 1.10 [ 0.79, 1.54 ]
Total (95% CI) 10113 10059 100.0 % 1.10 [ 0.79, 1.54 ]
Total events: 72 (Tranexamic acid), 65 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 18 Non-prespecified composite outcome: death or hysterectomy.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 18 Non-prespecified composite outcome: death or hysterectomy
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 534/10032 546/9985 100.0 % 0.97 [ 0.87, 1.09 ]
Total (95% CI) 10032 9985 100.0 % 0.97 [ 0.87, 1.09 ]
Total events: 534 (Tranexamic acid), 546 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 19 Blood loss 500 mL or more after randomisation.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 19 Blood loss 500 mL or more after randomisation
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 (1) 12/77 23/74 100.0 % 0.50 [ 0.27, 0.93 ]
Total (95% CI) 77 74 100.0 % 0.50 [ 0.27, 0.93 ]
Total events: 12 (Tranexamic acid), 23 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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(1) Blood loss between randomisation and 6 hours
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Analysis 1.20. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 20 Blood loss 1000 mL or more after randomisation.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 20 Blood loss 1000 mL or more after randomisation
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 (1) 4/77 8/74 100.0 % 0.48 [ 0.15, 1.53 ]
Total (95% CI) 77 74 100.0 % 0.48 [ 0.15, 1.53 ]
Total events: 4 (Tranexamic acid), 8 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
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(1) Blood loss from randomisation to 6 hours
Analysis 1.21. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 21 Mean blood loss (mL).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 21 Mean blood loss (mL)
Study or subgroup Tranexamic acid Placebo/std care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ducloy-Bouthors 2011 (1) 77 280 (320) 74 387 (409) 100.0 % -107.00 [ -224.44, 10.44 ]
Total (95% CI) 77 74 100.0 % -107.00 [ -224.44, 10.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 22 Blood transfusion (all).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 22 Blood transfusion (all)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 (1) 13/77 20/74 0.4 % 0.62 [ 0.34, 1.16 ]
Woman Trial 2017 5461/10033 5426/9983 99.6 % 1.00 [ 0.98, 1.03 ]
Total (95% CI) 10110 10057 100.0 % 1.00 [ 0.97, 1.03 ]
Total events: 5474 (Tranexamic acid), 5446 (Placebo/std care)
Heterogeneity: Chi2 = 2.22, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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(1) At day 42
57Antifibrinolytic drugs for treating primary postpartum haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.23. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 23 Blood products transfusion.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 23 Blood products transfusion
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Frozen plasma
Woman Trial 2017 889/10031 856/9982 100.0 % 1.03 [ 0.94, 1.13 ]
Subtotal (95% CI) 10031 9982 100.0 % 1.03 [ 0.94, 1.13 ]
Total events: 889 (Tranexamic acid), 856 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Other product transfusion
Woman Trial 2017 147/10031 157/9982 100.0 % 0.93 [ 0.75, 1.16 ]
Subtotal (95% CI) 10031 9982 100.0 % 0.93 [ 0.75, 1.16 ]
Total events: 147 (Tranexamic acid), 157 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
3 Any transfusion
Woman Trial 2017 5498/10033 5459/9883 100.0 % 0.99 [ 0.97, 1.02 ]
Subtotal (95% CI) 10033 9883 100.0 % 0.99 [ 0.97, 1.02 ]
Total events: 5498 (Tranexamic acid), 5459 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 1.07, df = 2 (P = 0.59), I2 =0.0%
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Analysis 1.24. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 24 Post randomisation additional uterotonics.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 24 Post randomisation additional uterotonics
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 (1) 36/72 34/72 0.3 % 1.06 [ 0.76, 1.48 ]
Woman Trial 2017 9996/10034 9930/9984 99.7 % 1.00 [ 1.00, 1.00 ]
Total (95% CI) 10106 10056 100.0 % 1.00 [ 1.00, 1.00 ]
Total events: 10032 (Tranexamic acid), 9964 (Placebo/std care)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 25 Post randomisation additional uterotonics.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 25 Post randomisation additional uterotonics
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prostaglandin
Ducloy-Bouthors 2011 36/72 34/72 4.5 % 1.06 [ 0.76, 1.48 ]
Woman Trial 2017 689/10034 722/9984 95.5 % 0.95 [ 0.86, 1.05 ]
Subtotal (95% CI) 10106 10056 100.0 % 0.95 [ 0.87, 1.05 ]
Total events: 725 (Tranexamic acid), 756 (Placebo/std care)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Oxytocin
Woman Trial 2017 9940/10034 9865/9984 100.0 % 1.00 [ 1.00, 1.01 ]
Subtotal (95% CI) 10034 9984 100.0 % 1.00 [ 1.00, 1.01 ]
Total events: 9940 (Tranexamic acid), 9865 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
3 Ergometrine
Woman Trial 2017 4326/10034 4314/9984 100.0 % 1.00 [ 0.97, 1.03 ]
Subtotal (95% CI) 10034 9984 100.0 % 1.00 [ 0.97, 1.03 ]
Total events: 4326 (Tranexamic acid), 4314 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
4 Misoprostol
Woman Trial 2017 6707/10034 6717/9984 100.0 % 0.99 [ 0.97, 1.01 ]
Subtotal (95% CI) 10034 9984 100.0 % 0.99 [ 0.97, 1.01 ]
Total events: 6707 (Tranexamic acid), 6717 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi2 = 1.87, df = 3 (P = 0.60), I2 =0.0%
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.26. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 26 Hysterectomy (provided it is not part of the intervention under
investigation).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 26 Hysterectomy (provided it is not part of the intervention under investigation)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ducloy-Bouthors 2011 0/77 1/74 0.4 % 0.32 [ 0.01, 7.74 ]
Woman Trial 2017 (1) 358/10032 351/9985 99.6 % 1.02 [ 0.88, 1.17 ]
Total (95% CI) 10109 10059 100.0 % 1.01 [ 0.88, 1.17 ]
Total events: 358 (Tranexamic acid), 352 (Placebo/std care)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
(1) Denominators not clear in published report; clarified with trialists.
Analysis 1.27. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 27 Hysterectomy to control bleeding.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 27 Hysterectomy to control bleeding
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 (1) 283/10032 295/9985 100.0 % 0.95 [ 0.81, 1.12 ]
Total (95% CI) 10032 9985 100.0 % 0.95 [ 0.81, 1.12 ]
Total events: 283 (Tranexamic acid), 295 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours TXA Favours placebo/std care
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(1) Denominators in published trial report not clear; clarified with trialist
Analysis 1.28. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 28 Post randomisation surgical intervention to control bleeding.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 28 Post randomisation surgical intervention to control bleeding
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Arterial ligation
Ducloy-Bouthors 2011 0/77 1/74 0.6 % 0.32 [ 0.01, 7.74 ]
Woman Trial 2017 225/10032 254/9985 99.4 % 0.88 [ 0.74, 1.05 ]
Subtotal (95% CI) 10109 10059 100.0 % 0.88 [ 0.74, 1.05 ]
Total events: 225 (Tranexamic acid), 255 (Placebo/std care)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Embolisation
Ducloy-Bouthors 2011 5/77 5/74 28.1 % 0.96 [ 0.29, 3.18 ]
Woman Trial 2017 10/10032 13/9985 71.9 % 0.77 [ 0.34, 1.75 ]
Subtotal (95% CI) 10109 10059 100.0 % 0.82 [ 0.42, 1.62 ]
Total events: 15 (Tranexamic acid), 18 (Placebo/std care)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
3 Late postpartum curettage (after day 7)
Ducloy-Bouthors 2011 1/77 2/74 100.0 % 0.48 [ 0.04, 5.19 ]
Subtotal (95% CI) 77 74 100.0 % 0.48 [ 0.04, 5.19 ]
Total events: 1 (Tranexamic acid), 2 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
4 Intrauterine tamponade
Woman Trial 2017 705/10032 729/9985 100.0 % 0.96 [ 0.87, 1.06 ]
Subtotal (95% CI) 10032 9985 100.0 % 0.96 [ 0.87, 1.06 ]
Total events: 705 (Tranexamic acid), 729 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
(Continued . . . )
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(. . . Continued)
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
5 Manual removal of placenta
Woman Trial 2017 918/10032 961/9985 100.0 % 0.95 [ 0.87, 1.04 ]
Subtotal (95% CI) 10032 9985 100.0 % 0.95 [ 0.87, 1.04 ]
Total events: 918 (Tranexamic acid), 961 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
6 Laparotomy for bleeding
Woman Trial 2017 82/10032 127/9985 100.0 % 0.64 [ 0.49, 0.85 ]
Subtotal (95% CI) 10032 9985 100.0 % 0.64 [ 0.49, 0.85 ]
Total events: 82 (Tranexamic acid), 127 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
7 Brace sutures
Woman Trial 2017 300/10032 250/9985 100.0 % 1.19 [ 1.01, 1.41 ]
Subtotal (95% CI) 10032 9985 100.0 % 1.19 [ 1.01, 1.41 ]
Total events: 300 (Tranexamic acid), 250 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Chi2 = 16.32, df = 6 (P = 0.01), I2 =63%
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.29. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 29 Side effects of the intervention: any maternal vascular occlusive event.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 29 Side effects of the intervention: any maternal vascular occlusive event
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 30/10033 34/9985 100.0 % 0.88 [ 0.54, 1.43 ]
Total (95% CI) 10033 9985 100.0 % 0.88 [ 0.54, 1.43 ]
Total events: 30 (Tranexamic acid), 34 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours TXA Favours placebo/std care
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Analysis 1.30. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 30 Side effects of the intervention: maternal vascular occlusive events.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 30 Side effects of the intervention: maternal vascular occlusive events
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT
Ducloy-Bouthors 2011 2/77 1/74 12.7 % 1.92 [ 0.18, 20.75 ]
Woman Trial 2017 3/10033 7/9985 87.3 % 0.43 [ 0.11, 1.65 ]
Subtotal (95% CI) 10110 10059 100.0 % 0.62 [ 0.20, 1.88 ]
Total events: 5 (Tranexamic acid), 8 (Placebo/std care)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Pulmonary embolism
Woman Trial 2017 17/10033 20/9985 100.0 % 0.85 [ 0.44, 1.61 ]
Subtotal (95% CI) 10033 9985 100.0 % 0.85 [ 0.44, 1.61 ]
Total events: 17 (Tranexamic acid), 20 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Myocardial infarction
Woman Trial 2017 2/10033 3/9985 100.0 % 0.66 [ 0.11, 3.97 ]
Subtotal (95% CI) 10033 9985 100.0 % 0.66 [ 0.11, 3.97 ]
Total events: 2 (Tranexamic acid), 3 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
4 Stroke
Woman Trial 2017 8/10033 6/9985 100.0 % 1.33 [ 0.46, 3.82 ]
Subtotal (95% CI) 10033 9985 100.0 % 1.33 [ 0.46, 3.82 ]
Total events: 8 (Tranexamic acid), 6 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 1.07, df = 3 (P = 0.78), I2 =0.0%
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.31. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 31 Quality of Life: EQ5D Mobility.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 31 Quality of Life: EQ5D Mobility
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 30/9805 31/9728 100.0 % 0.96 [ 0.58, 1.58 ]
Total (95% CI) 9805 9728 100.0 % 0.96 [ 0.58, 1.58 ]
Total events: 30 (Tranexamic acid), 31 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours tranexamic acid Favours placebo/std care
Analysis 1.32. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 32 Quality of Life: EQ5D Self care.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 32 Quality of Life: EQ5D Self care
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 39/9805 31/9728 100.0 % 1.25 [ 0.78, 2.00 ]
Total (95% CI) 9805 9728 100.0 % 1.25 [ 0.78, 2.00 ]
Total events: 39 (Tranexamic acid), 31 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.33. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 33 Quality of Life: EQ5D Usual activities.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 33 Quality of Life: EQ5D Usual activities
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 38/9805 44/9728 100.0 % 0.86 [ 0.56, 1.32 ]
Total (95% CI) 9805 9728 100.0 % 0.86 [ 0.56, 1.32 ]
Total events: 38 (Tranexamic acid), 44 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
Analysis 1.34. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 34 Quality of Life: EQ5D Pain/discomfort.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 34 Quality of Life: EQ5D Pain/discomfort
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 13/9805 18/9728 100.0 % 0.72 [ 0.35, 1.46 ]
Total (95% CI) 9805 9728 100.0 % 0.72 [ 0.35, 1.46 ]
Total events: 13 (Tranexamic acid), 18 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
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Analysis 1.35. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 35 Quality of Life: EQ5D Anxiety/depression.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 35 Quality of Life: EQ5D Anxiety/depression
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 30/9805 29/9728 100.0 % 1.03 [ 0.62, 1.71 ]
Total (95% CI) 9805 9728 100.0 % 1.03 [ 0.62, 1.71 ]
Total events: 30 (Tranexamic acid), 29 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours tranexamic acid Favours placebo/std care
Analysis 1.36. Comparison 1 Standard care plus IV tranexamic acid versus placebo or standard care alone
for the treatment of PPH, Outcome 36 Side effects of the intervention: neonatal vascular occlusive event.
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 1 Standard care plus IV tranexamic acid versus placebo or standard care alone for the treatment of PPH
Outcome: 36 Side effects of the intervention: neonatal vascular occlusive event
Study or subgroup Tranexamic acid Placebo/std care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Woman Trial 2017 0/10033 0/9985 Not estimable
Total (95% CI) 10033 9985 Not estimable
Total events: 0 (Tranexamic acid), 0 (Placebo/std care)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.1. Comparison 2 Tranexamic acid versus rectal misoprostol for the treatment of PPH, Outcome
1 Mean blood loss (mL).
Review: Antifibrinolytic drugs for treating primary postpartum haemorrhage
Comparison: 2 Tranexamic acid versus rectal misoprostol for the treatment of PPH
Outcome: 1 Mean blood loss (mL)
Study or subgroup TXA Misoprostol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sahaf 2014 100 1.2 (0.33) 100 1.18 (0.47) 100.0 % 0.02 [ -0.09, 0.13 ]
Total (95% CI) 100 100 100.0 % 0.02 [ -0.09, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours TXA Favours misoprostol
A P P E N D I C E S
Appendix 1. Search methods used in ICTRP and ClinicalTrials.gov
ICTRP
Each line was run separately
tranexamic AND labo(u)r
TXA AND labo(u)r
aprotinin AND labo(u)r
epsilon-aminocaproic AND labo(u)r
aminomethylbenzoic AND labo(u)r
antifibrinolytic AND labo(u)r
tranexamic AND postpartum AND h(a)emorrhage
TXA AND postpartum AND h(a)emorrhage
aprotinin AND postpartum AND h(a)emorrhage
epsilon-aminocaproic AND postpartum AND h(a)emorrhage
aminomethylbenzoic AND postpartum AND h(a)emorrhage
antifibrinolytic AND postpartum AND h(a)emorrhage
ClinicalTrials.gov
Advanced search, Intervention studies
Intervention/Treatment : antifibrinolytic; aprotinin; tranexamic acid; epsilon-aminocaproic acid; aminomethylbenzoic
Condition: Postpartum hemorrhage
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External sources
• WHO UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in
Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol for this Cochrane review (Shakur 2017) was published in PROSPERO on 18 July 2017 - see https://www.crd.york.ac.uk/
PROSPERO/display record.asp?ID=CRD42017071200. The protocol was not published in the Cochrane Library.
There are some differences between our published protocol and this full review. These are outlined below.
Assessment of the quality of the evidence using GRADE
Outcomes for use in GRADE
We have edited ’Surgical treatment (hysterectomy, arterial ligation, compressive uterine sutures, arterial embolization)’ to ’Surgical
intervention to control bleeding’ for consistency with the main methods/list of outcomes and for the purposes of GRADE we have
restricted the outcome to hysterectomy.
We have removed the following outcomes from the list of outcomes for use in GRADE: non-surgical intervention to control bleeding
(uterine packing, bimanual uterine massage, tamponade, external aortic compression and compression garments). Shock and maternal
quality of life were also amongst our GRADE outcomes for inclusion in our ’Summary of findings’ table. Shock was not reported in
either of the trials included in the review; we have therefore presented data for maternal blood transfusion and blood loss ≥500 mL
in our ’Summary of findings’ table. While maternal quality of life was reported in the WOMAN trial, this was for the five separate
domains on the EQ5D; we have therefore reported results in the text rather than as five separate outcomes in the ’Summary of findings’
table.
Side effects of the intervention (both maternal and for breastfed neonates); specifically vascular occlusive events (myocardial infarction,
stroke, deep vein thrombosis or pulmonary embolism) and renal failure) has been restricted to maternal vascular occlusive events only
for the purposes of GRADE.
Main comparisons for use in GRADE
We have also added further main comparisons to be considered using GRADE in future updates of this review: standard care plus
systemic aprotinin, tranexamic acid (TXA), epsilon-aminocaproic acid (EACA) and aminomethylbenzoic acid versus standard care plus
topic antifibrinolytic; standard care plus one antifibrinolytic drug therapy versus another.
Outcomes
An important outcome in the Woman Trial 2017 was a composite outcome “death or hysterectomy”. We have included this non-
prespecified outcome in our data and analyses.
We have edited ’Surgical treatment (hysterectomy, arterial ligation, compressive uterine sutures, arterial embolization)’ to ’Surgical
intervention used to control bleeding (hysterectomy, arterial ligation, compressive uterine sutures, arterial embolisation, laparotomy).
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